[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540501":3},{"organization":4,"outcomesModule":7,"designInfo":79,"detailedDescription":86,"studyPopulation":82,"armGroups":87,"interventions":148,"overallOfficials":775,"centralContacts":82,"locations":780,"responsibleParty":2450,"collaborators":82,"id":2452,"slug":2453,"hasResults":2454,"nctId":2455,"briefTitle":2456,"officialTitle":2457,"acronym":82,"eligibilityCriteria":2458,"healthyVolunteers":2454,"sex":2459,"minAge":82,"maxAge":2460,"enrollmentInfo":2461,"targetDuration":82,"studyType":2464,"phases":2465,"briefSummary":2467,"conditions":2468,"keywords":82,"overallStatus":783,"whyStopped":82,"lastUpdateSubmitDate":2471,"lastUpdatePostDateStruct":2472,"startDateStruct":2475,"completionDateStruct":2477,"leadSponsor":2479,"locationsCount":2480},{"fullName":5,"class":6},"National Cancer Institute (NCI)","NIH",{"primaryOutcomes":8,"secondaryOutcomes":21,"otherOutcomes":44},[9,13,17],{"measure":10,"description":11,"timeFrame":12},"Incidence of dose-limiting toxicities (DLTs) (safety phase)","For the safety phase, DLTs of the induction + venetoclax cycle of KMT2A-rearranged (R) patients will be assessed.","For the duration of the induction + venetoclax cycle",{"measure":14,"description":15,"timeFrame":16},"Incidence of DLTs (expansion phase)","For the expansion phase, DLTs of Arm B will be assessed and monitored for the cycles that contain venetoclax (induction, consolidation, and MARMA cycles of Arm B).","During the induction, consolidation, and MARMA cycles of Arm B",{"measure":18,"description":19,"timeFrame":20},"Minimal residual disease (MRD)-negative remission rate","The end of induction MRD-negative remission rate will be compared between Arm A and Arm B. MRD negativity is defined as achievement of complete remission and MRD \\\u003C 0.01% by flow cytometry. The MRD-negative remission rate at the end of induction between Arm A and Arm B will be compared using a one-sided Z test of proportions with Type I error of 0.15.","At the end of induction",[22,25,29,32,36,40],{"measure":23,"description":24,"timeFrame":20},"MRD-negative remission rate","MRD-negative remission rate at the end of induction and the standard error or 95% confidence interval will be estimated among infants with KMT2A-R acute lymphoblastic leukemia (ALL) treated with venetoclax at the RP2D. This analysis will include eligible KMT2A-R patients treated with venetoclax at the RP2D in the safety phase, as well as patients randomized to Arm B and treated with venetoclax in the expansion phase. MRD negativity is defined as \\\u003C 0.01% by flow cytometry.",{"measure":26,"description":27,"timeFrame":28},"Event free survival (EFS) rates of infants with KMT2A-R ALL","The EFS rates from date of randomization of Arm B will be compared to Arm A. Comparison of EFS rates between Arm A and Arm B will be based on a one-sided logrank test with Type I error of 0.15. In addition, EFS rates will be estimated using the Kaplan-Meier method with Greenwood standard errors. Hazard ratios and confidence intervals will be estimated based on Cox regression models as appropriate. Cumulative incidence rates of each EFS event type (relapse, treatment failure, secondary malignant neoplasm and death) will also be estimated and presented with cumulative incidence curves and compared between arms as appropriate.","From date of randomization to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years",{"measure":30,"description":31,"timeFrame":28},"3-year EFS of infants with KMT2A-R ALL","For Arm A, the 3-year EFS rate (representing a plateau rate based on the shape of EFS curves of historical data in this patient population) from the date of randomization will be compared to the stable historical 3-year EFS rate of 35% observed in AALL0631 and other international trials.",{"measure":33,"description":34,"timeFrame":35},"Proportion of KMT2A-germline (G) patients in Arm C who are able to receive all treatment cycles before maintenance","The feasibility of treating KMT2A-G patients with a high-risk ALL backbone and two cycles of blinatumomab (Arm C) will be assessed. Arm C treatment will be considered feasible for KMT2A-G patients if the proportion of KMT2A-G patients in Arm C who are able to receive all treatment cycles before maintenance (i.e., up to interim maintenance 2) is more than 76.8%. The proportion of patients receiving all cycles before Maintenance will be compared to 76.8% with a one-sample exact test of proportion with Type I error of 0.15.","Up to interim maintenance 2",{"measure":37,"description":38,"timeFrame":39},"3-year EFS of infants with KMT2A-G ALL treated on Arm C","The 3-year EFS rate from date of enrollment of KMT2A-G patients in Arm C will be estimated with the Kaplan-Meier method.","From date of enrollment to treatment failure, first documented relapse following achievement of remission-1, occurrence of a second or secondary malignant neoplasm, or death, assessed up to 3 years",{"measure":41,"description":42,"timeFrame":43},"Pharmacokinetics (PK) of venetoclax in infants","PK samples will be collected from patients enrolled in the safety phase of the study as well as from patients randomized to Arm B in the expansion phase who consent to participate, to determine the major secondary objective of characterizing the PK of venetoclax in infants. PK samples will be evaluated in batches and standard nonlinear mixed effect modeling will be used for model building and refinement of time-concentration data. After model refinement, a non-parametric bootstrap analysis will be performed reporting the 95% confidence intervals for each PK parameter.","On days 7, 10, and 14 of induction",[45,48,52,56,60,64,68,72,75],{"measure":46,"description":47,"timeFrame":28},"3-year EFS of infants with KMT2A-R ALL treated on Arm B","Arm B, the 3-year EFS rate from date of randomization will be estimated, and will be compared to Arm A as described in the secondary objective, and to historical 3-year EFS. Comparison to historical rate will be based on a one-sample test of proportion with one-sided Type I error of 0.15.",{"measure":49,"description":50,"timeFrame":51},"Use of high-throughput sequencing (HTS) for MRD detection in infant ALL compared to centralized flow cytometry","Pre-treatment HTS clonality and HTS MRD tracking results will be collected and compared to the required centralized flow cytometry-based MRD data to evaluate the feasibility and prognostic utility of HTS MRD evaluation in the infant ALL population.","Up to 3 years",{"measure":53,"description":54,"timeFrame":55},"PK of calaspargase pegol in infants with ALL","PK of calaspargase pegol will be analyzed by monitoring asparaginase activity levels. Once a PK model is developed for calaspargase pegol, standard regression analysis will be used to describe the relationship between drug exposure and asparaginase activity. Additionally, asparaginase-associated toxicities will be described for the entire study population and correlated with activity levels when possible. The result of this analysis will be an estimation of potential optimal exposure expected to yield the maximum efficacy while limiting toxicity. These analyses will be exploratory and descriptive.","At completion of the trial, up to 3 years",{"measure":57,"description":58,"timeFrame":59},"Incidence of CD19-negative relapse and myeloid switch relapse with protocol therapy","For patients who experience relapse, will collect information regarding the immunophenotype of the leukemic blasts at time of relapse. Will report on the rate of CD19 negative relapse as well as myeloid switch relapse for all patients enrolled on study. This analysis will be exploratory and descriptive.","At the time of relapse, up to 3 years",{"measure":61,"description":62,"timeFrame":63},"Impact of venetoclax in combination with chemotherapy on T-cell subsets and function","BCL-2 inhibition is reported to alter T-cell subsets, including increased activation, enhanced cytotoxicity against leukemia cells and heightened resistance to cell death. Peripheral blood and bone marrow samples will be collected prior to and following the first course of venetoclax to evaluate effects on T-cell subsets and function following venetoclax exposure.","Prior to and following the first course of venetoclax",{"measure":65,"description":66,"timeFrame":67},"Feasibility of T-cell collection and success of T-cell manufacturing for infants with KMT2A-R ALL who receive chimeric antigen receptor (CAR) T-cell therapy","For patients that undergo T-cell collection, will collect data regarding the feasibility of T-cell collection in the context of protocol therapy. Additionally, for patients who proceed with CAR T-cell therapy after coming off protocol therapy, will collect data regarding the success of T-cell manufacturing, infusion and response to therapy in this young population, as the success of this subsequent therapy may be heavily impacted by the effect of protocol therapy on T-cell function. These analyses will be exploratory and descriptive.","After coming off protocol therapy",{"measure":69,"description":70,"timeFrame":71},"Predictors of response and resistance to venetoclax and overall protocol therapy","Will study the inter- and intra- patient variability in the expression of apoptotic proteins (e.g., BCL-2, MCL-1, BCL-XL) and apoptotic priming at diagnosis and identify changes that occur during induction therapy in relationship to venetoclax exposure. Will then determine whether the state of BCL-2 specific apoptotic priming correlates with outcome. Will also integrate genomic and molecular features (such as developmental state, signaling, epigenomic, transcriptomic, proteomic and metabolomic states) before and after venetoclax exposure, for those assays where this type of analysis is feasible, to determine biomarkers of response and resistance to therapy for infants with ALL.","Before and after venetoclax exposure, up to 3 years",{"measure":73,"description":74,"timeFrame":67},"Impact of subsequent anti-cancer therapy on overall survival","For all patients who remain in study follow-up after coming off protocol therapy, data will be collected regarding subsequent cancer directed therapies received as well as relapse and survival status in order to evaluate the impact of subsequent cancer directed therapy on the overall survival of patients enrolled on this study. These analyses will be exploratory and descriptive.",{"measure":76,"description":77,"timeFrame":78},"Overall survival (OS) rates","Will compare OS rates of infants by arms and to historical OS rates. The OS rates from the date of randomization of patients with KMT2A-R ALL will be compared between Arm A and Arm B. Comparison of OS rates between Arm A and Arm B will be based on a one-sided logrank test with Type I error of 0.15. In addition, OS rates of KMT2A-R patients in Arm A and Arm B will be compared to historical rates observed in similar patients in completed studies such as AALL0631 or AALL15P1. In addition, OS from enrollment of KMT2A-G patients will be compared to historical rates. OS rates will be estimated using the Kaplan-Meier method with Greenwood standard errors. Hazard ratios and confidence intervals will be estimated based on Cox regression models as appropriate. These analyses will be largely exploratory.","From randomization to death due to any cause, up to 3 years",{"allocation":80,"interventionModel":81,"interventionModelDescription":82,"primaryPurpose":83,"observationalModel":82,"timePerspective":82,"maskingInfo":84},"RANDOMIZED","SEQUENTIAL",null,"TREATMENT",{"masking":85,"maskingDescription":82,"whoMasked":82},"NONE","PRIMARY OBJECTIVES:\n\nI. To evaluate the safety and tolerability of venetoclax in addition to a standard chemotherapy backbone and two cycles of blinatumomab in infants (aged 365 days or less at diagnosis) with newly diagnosed KMT2A-R ALL.\n\nII. To determine in a randomized manner if the addition of venetoclax to induction chemotherapy improves end of induction minimal residual disease (MRD)-negative remission rates in infants with KMT2A-R ALL.\n\nSECONDARY OBJECTIVES:\n\nI. To estimate the MRD-negative remission rate for all eligible infants with KMT2A-R ALL treated with venetoclax at the recommended phase 2 dose (RP2D).\n\nII. To compare event free survival (EFS) rates of infants with KMT2A-R ALL treated on arm B to those treated on arm A.\n\nIII. To compare 3-year EFS rates of infants with KMT2A-R ALL treated on arm A to historical controls.\n\nIV. To determine the feasibility of treating infants with KMT2A-G ALL with a Children's Oncology Group (COG) high risk ALL chemotherapy backbone and two cycles of blinatumomab and estimate the 3-year EFS rate of infants with KMT2A-G ALL treated on arm C.\n\nV. To characterize the pharmacokinetics (PK) of venetoclax in infants.\n\nEXPLORATORY OBJECTIVES:\n\nI. To describe 3-year EFS rate of infants with KMT2A-R ALL treated on arm B. II. To evaluate the use of high-throughput sequencing (HTS) for MRD detection in infant ALL compared to centralized flow cytometry.\n\nIII. To characterize the PK of calaspargase pegol in infants with ALL. IV. To report the incidence of CD19 negative relapse and myeloid switch relapse with protocol therapy.\n\nV. To evaluate the impact of venetoclax in combination with chemotherapy on T-cell subsets and function.\n\nVI. To describe the feasibility of T-cell collection and success of T-cell manufacturing for infants with KMT2A-R ALL who receive chimeric antigen receptor (CAR) T- cell therapy after coming off protocol therapy.\n\nVII. To determine predictors of response and resistance to venetoclax and overall protocol therapy.\n\nVIII. To evaluate the impact of subsequent anti-cancer therapy on overall survival after coming off protocol therapy.\n\nIX. To compare overall survival (OS) rates of infants by arms and to historical OS rates.\n\nOUTLINE:\n\nSTEROID PREPHASE: All patients receive prednisone or prednisolone orally (PO) or nasogastrically (NG) three times daily (TID) or methylprednisolone intravenously (IV) TID for 7 days prior to the start of induction therapy (on days 1-7).\n\nPatients who are KMT2A gene rearrangement positive are assigned to the safety phase cohort during the safety phase of the study, or randomized between Arm A and Arm B during the expansion phase of the study. Patients who are KMT2A gene rearrangement negative are assigned to Arm C.\n\nSAFETY PHASE COHORT (CLOSED TO ACCRUAL 06\u002F03\u002F2026):\n\nINDUCTION: Patients receive venetoclax PO or NG once daily (QD) on days 1-7, 1-10, or 1-14, daunorubicin IV over 1-15 minutes on days 1 and 2, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy (methotrexate, hydrocortisone, cytarabine) intrathecally (IT) on days 1, 15, and 29 or days 1, 8, 15, 22, and 29. Patients with \\\u003C 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when absolute neutrophil counts (ANC) \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL. Patients with \\>= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.\n\nBLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD \\>= 1% or who have residual non-central nervous system (CNS) extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nCONSOLIDATION: Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine subcutaneously (SC) QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD \\>= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nMARMA: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nBLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nDELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nMAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.\n\nEXPANSION PHASE: After completion of Safety phase, patients who are KMT2A gene rearrangement positive are randomized to Arm A or Arm B.\n\nARM A:\n\nINDUCTION: Patients receive daunorubicin IV over 1-15 minutes on days 1 and 2, cytarabine SC or IV over 1-30 minutes on days 1-14, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29, or days 1, 8, 15, 22, and 29. Patients with \\\u003C 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL. Patients with \\>= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.\n\nBLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD \\>= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nCONSOLIDATION: Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD \\>= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nMARMA: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nBLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nDELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nMAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.\n\nARM B: Patients are assigned to 1 of 4 cohorts.\n\nCOHORT 1:\n\nINDUCTION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14, daunorubicin IV over 1-15 minutes on days 1 and 2, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29 or days 1, 8, 15, 22, and 29. Patients with \\\u003C 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL. Patients with \\>= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.\n\nBLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD \\>= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nCONSOLIDATION: Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD \\>= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nMARMA + VENETOCLAX: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, venetoclax PO or NG QD on days 22-35, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nBLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nDELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nMAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.\n\nCOHORT 2:\n\nINDUCTION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14, daunorubicin IV over 1-15 minutes on days 1 and 2, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29 or days 1, 8, 15, 22, and 29. Patients with \\\u003C 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL. Patients with \\>= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.\n\nBLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD \\>= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nCONSOLIDATION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14 and 29-42, cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD \\>= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nMARMA: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nBLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nDELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nMAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.\n\nCOHORT 3:\n\nINDUCTION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14, daunorubicin IV over 1-15 minutes on days 1 and 2, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29 or days 1, 8, 15, 22, and 29. Patients with \\\u003C 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL. Patients with \\>= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.\n\nBLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD \\>= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nCONSOLIDATION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14 and 29-42, cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD \\>= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nMARMA + VENETOCLAX: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, venetoclax PO or NG QD on days 22-35, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nBLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nDELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nMAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.\n\nCOHORT 4:\n\nINDUCTION + VENETOCLAX: Patients receive venetoclax PO or NG QD on days 1-14, daunorubicin IV over 1-15 minutes on days 1 and 2, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29 or days 1, 8, 15, 22, and 29. Patients with \\\u003C 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL. Patients with \\>= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.\n\nBLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and intrathecal therapy IT on days 15 and 29. Patients who are MRD \\>= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nCONSOLIDATION: Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, and intrathecal therapy IT on day 29. Patients who are MRD \\>= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to MARMA the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nMARMA: Patients receive mercaptopurine PO or NG QD on days 1-14, high dose methotrexate IV over 24 hours on days 1 and 8, leucovorin PO, NG, or IV or levoleucovorin IV on days 3-4 and 10-11, intrathecal therapy IT on days 1 and 8, high dose cytarabine IV over 3 hours on days 22-23 and 29-30, and recombinant crisantaspase IM on days 23 and 30. At the end of MARMA (day 49), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nBLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28 and intrathecal therapy IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nDELAYED INTENSIFICATION: Patients receive calaspargase pegol IV over 1-2 hours on day 1, dexamethasone PO, NG, or IV TID on days 1-21, thioguanine PO or NG on days 1-28 and 36-49, vincristine IV on days 1, 8, 15, and 22, daunorubicin IV over 1-15 minutes on days 1, 8, 15, and 22, cytarabine SC or IV over 1-30 minutes on days 2-5, 9-12, 16-19, 23-26, 37-40, and 44-47, cyclophosphamide IV over 15-30 minutes on days 36 and 50, and intrathecal therapy IT on days 1 and 15. At the end of delayed intensification (day 63), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nMAINTENANCE: Patients receive mercaptopurine PO or NG on days 1-84 of each cycle, methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle, and intrathecal therapy IT on day 1 of cycles 1-3. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of MARMA in the absence of disease progression or unacceptable toxicity.\n\nARM C:\n\nINDUCTION: Patients receive daunorubicin IV over 1-15 minutes on days 1 and 2, cytarabine SC or IV over 1-30 minutes on days 1-14, vincristine IV on days 1, 8, 15, and 22, dexamethasone PO, NG, or IV TID on days 1-28, calaspargase pegol IV over 1-2 hours on day 4, and intrathecal therapy IT on days 1, 15, and 29, or days 1, 8, 15, 22, and 29. Patients with \\\u003C 5% blasts by morphology in the bone marrow at the end of induction (day 35) proceed directly to blinatumomab block 1 on the next day or when ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL. Patients with \\>= 5% blasts by morphology in the bone marrow at the end of induction proceed to blinatumomab block 1 as soon as marrow results are known, irrespective of ANC or platelet values.\n\nBLINATUMOMAB BLOCK 1: Patients receive dexamethasone PO, NG, or IV on day 1 or days 1 and 8, blinatumomab IV on days 1-28, 1-7, or 8-28, and methotrexate IT on days 15 and 29. Patients who are MRD \\>= 1% or who have residual non-CNS extramedullary disease at the end of blinatumomab block 1 (day 35) discontinue protocol therapy. All other patients proceed directly to consolidation on the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nCONSOLIDATION: Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 29, cytarabine SC QD or IV over 1-30 minutes on days 1-4, 8-11, 29-32, and 36-39, mercaptopurine PO or NG QD on days 1-14 and 29-42, methotrexate IT on days 8, 15, and 22, vincristine IV on days 15, 22, 43, and 50, and calaspargase pegol IV over 1-2 hours on days 15 and 43. Patients who are MRD \\>= 0.01% at the end of consolidation therapy (day 56) discontinue protocol therapy. All other patients proceed directly to interim maintenance 1 the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nINTERIM MAINTENANCE 1: Patients receive vincristine IV on days 1, 15, 29, and 43, high dose methotrexate IV over 24 hours on days 1, 15, 29, and 43, mercaptopurine PO or NG on days 1-14, 15-28, 29-42, and 43-56, methotrexate IT on days 1 and 29, and leucovorin PO or NG or IV or levoleucovorin IV on days 3-4, 17-18, 31-32, and 45-46. At the end of interim maintenance 1 (day 63), all patients proceed directly to blinatumomab block 2 the next day or when peripheral counts recover to ANC \\>= 500\u002FuL and platelets \\>= 50,000\u002FuL.\n\nBLINATUMOMAB BLOCK 2: Patients receive blinatumomab IV on days 1-28, and methotrexate IT on days 1 and 15. At the end of blinatumomab block 2 (day 35), all patients proceed directly to delayed intensification the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nDELAYED INTENSIFICATION: Patients receive methotrexate IT on days 1, 29, and 36, dexamethasone PO, NG, or IV BID on days 1-7 and 15-21, vincristine IV on days 1, 8, 15, 43, and 50, doxorubicin IV over 3-15 minutes on days 1, 8, and 15, calaspargase pegol IV over 1-2 hours on days 4 and 43, cyclophosphamide IV over 30-60 minutes on day 29, thioguanine PO or NG on days 29-42, and cytarabine SC or IV over 1-30 minutes on days 29-32 and 36-39. At the end of delayed intensification (day 63), all patients proceed directly to interim maintenance 2 the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nINTERIM MAINTENANCE 2: Patients receive vincristine IV on days 1, 11, 21, 31, and 41, methotrexate IV push over 2-5 minutes or IV over 10-15 minutes on days 1, 11, 21, 31, and 41, methotrexate IT on days 1 and 31, and calaspargase pegol IV over 1-2 hours on days 2 and 23. At the end of interim maintenance 2 (day 56), all patients proceed directly to maintenance the next day or when peripheral counts recover to ANC \\>= 750\u002FuL and platelets \\>= 75,000\u002FuL.\n\nMAINTENANCE: Patients receive methotrexate IT on day 1 of cycles 1-3, vincristine IV on day 1 of each cycle, prednisone or prednisolone PO or NG BID or methylprednisolone IV BID on days 1-5 of each cycle, mercaptopurine PO or NG on days 1-84 of each cycle, and methotrexate PO, NG, or IV on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of each cycle. Cycles repeat every 12 weeks (84 days) for up to 2 years from the start of interim maintenance 1 in the absence of disease progression or unacceptable toxicity.\n\nAll patients undergo bone marrow aspiration, collection of blood samples and echocardiography (ECHO) or multigated acquisition scan (MUGA) throughout the trial. Patients may undergo computed tomography (CT), magnetic resonance imaging (MRI), fludeoxyglucose-positron emission tomography (FDG-PET), and\u002For lumbar puncture if clinically indicated.\n\nAfter completion of study treatment, patients are followed up for up to 3 years.",[88,115,120,124,128,132,140,144],{"label":89,"type":90,"description":91,"interventionNames":92},"Arm A","EXPERIMENTAL","See Detailed Description for Arm A.",[93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114],"Drug: Asparaginase Erwinia chrysanthemi","Procedure: Biospecimen Collection","Biological: Blinatumomab","Procedure: Bone Marrow Aspiration","Drug: Calaspargase Pegol","Procedure: Computed Tomography","Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Daunorubicin","Drug: Dexamethasone","Procedure: Echocardiography Test","Procedure: FDG-Positron Emission Tomography","Drug: Leucovorin","Drug: Levoleucovorin","Procedure: Lumbar Puncture","Procedure: Magnetic Resonance Imaging","Drug: Mercaptopurine","Drug: Methotrexate","Procedure: Multigated Acquisition Scan","Drug: Therapeutic Hydrocortisone","Drug: Thioguanine","Drug: Vincristine",{"label":116,"type":90,"description":117,"interventionNames":118},"Arm B, Cohort 1","See Detailed Description for Arm B, Cohort 1.",[93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,119,114],"Drug: Venetoclax",{"label":121,"type":90,"description":122,"interventionNames":123},"Arm B, Cohort 2","See Detailed Description for Arm B, Cohort 2.",[93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,119,114],{"label":125,"type":90,"description":126,"interventionNames":127},"Arm B, Cohort 3","See Detailed Description for Arm B, Cohort 3.",[93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,119,114],{"label":129,"type":90,"description":130,"interventionNames":131},"Arm B, Cohort 4","See Detailed Description for Arm B, Cohort 4.",[93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,119,114],{"label":133,"type":90,"description":134,"interventionNames":135},"Arm C","See Detailed Description for Arm C.",[94,95,96,97,98,99,100,101,102,136,103,104,105,106,107,108,109,110,137,111,138,139,112,113,114],"Drug: Doxorubicin","Drug: Methylprednisolone","Drug: Prednisolone","Drug: Prednisone",{"label":141,"type":90,"description":142,"interventionNames":143},"Safety Phase Cohort","See Detailed Description for Safety Phase Cohort. (CLOSED TO ACCRUAL 06\u002F03\u002F2026)",[93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,119,114],{"label":145,"type":90,"description":146,"interventionNames":147},"Steroid Prephase(prednisone, prednisolone, methylprednisolone)","All patients receive prednisone or prednisolone PO or NG TID or methylprednisolone IV TID for 7 days prior to the start of induction therapy (on days 1-7).",[94,96,98,103,104,107,108,137,111,138,139],[149,173,183,201,205,215,232,278,315,325,395,403,410,418,423,434,441,461,501,542,576,594,651,697,725,753,767],{"type":150,"name":151,"description":152,"armGroupLabels":153,"otherNames":154},"DRUG","Asparaginase Erwinia chrysanthemi","Given recombinant crisantaspase IM or crisantaspase IM or IV",[89,116,121,125,129,141],[155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172],"Asparaginase Erwinia chrysanthemi (Recombinant)-rywn","Asparaginase Erwinia chrysanthemi, Recombinant-rywn","Asparaginase Erwinia chrysanthemi-rywn","Crisantaspase","Crisantaspase Biobetter JZP-458","Crisantaspasum","Enrylaze","Erwinase","Erwinaze","JZP 458","JZP-458","JZP458","PF743","RC-P JZP-458","Recombinant Asparaginase erwinia chrysanthemi JZP-458","Recombinant Crisantaspase JZP-458","Recombinant Erwinia asparaginase JZP-458","Rylaze",{"type":174,"name":175,"description":176,"armGroupLabels":177,"otherNames":178},"PROCEDURE","Biospecimen Collection","Undergo collection of blood samples",[89,116,121,125,129,133,141,145],[179,180,181,182],"Biological Sample Collection","Biospecimen Collected","Sample Collection","Specimen Collection",{"type":184,"name":185,"description":186,"armGroupLabels":187,"otherNames":188},"BIOLOGICAL","Blinatumomab","Given IV",[89,116,121,125,129,133,141],[189,190,191,192,193,194,195,196,197,198,199,200],"AMG 103","AMG-103","AMG103","Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody","Anti-CD19\u002FAnti-CD3 Recombinant Bispecific Monoclonal Antibody MT103","Blincyto","MEDI 538","MEDI-538","MEDI538","MT 103","MT-103","MT103",{"type":174,"name":202,"description":203,"armGroupLabels":204,"otherNames":82},"Bone Marrow Aspiration","Undergo bone marrow aspiration",[89,116,121,125,129,133,141,145],{"type":150,"name":206,"description":186,"armGroupLabels":207,"otherNames":208},"Calaspargase Pegol",[89,116,121,125,129,133,141],[209,210,211,212,213,214],"Asparaginase (Escherichia coli Isoenzyme II), Conjugate with alpha-(((2,5-Dioxo-1-pyrrolidinyl)oxy)carbonyl)-omega-methoxypoly(oxy-1,2-ethanediyl)","Asparlas","Calaspargase Pegol-mknl","EZN-2285","SC-PEG E. Coli L-Asparaginase","Succinimidyl Carbonate Monomethoxypolyethylene Glycol E. coli L-Asparaginase",{"type":174,"name":216,"description":217,"armGroupLabels":218,"otherNames":219},"Computed Tomography","Undergo CT",[89,116,121,125,129,133,141,145],[220,221,222,223,224,225,226,227,228,229,230,231],"CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","Diagnostic CAT Scan","Diagnostic CAT Scan Service Type","tomography",{"type":150,"name":233,"description":186,"armGroupLabels":234,"otherNames":235},"Cyclophosphamide",[89,116,121,125,129,133,141],[236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,276,277],"(-)-Cyclophosphamide","2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate","Asta B 518","B 518","B-518","B518","Carloxan","Ciclofosfamida","Ciclofosfamide","Cicloxal","Clafen","Claphene","CP monohydrate","CTX","CYCLO-cell","Cycloblastin","Cycloblastine","Cyclophospham","Cyclophosphamid monohydrate","Cyclophosphamide Monohydrate","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphanum","Cyclostin","Cyclostine","Cytophosphan","Cytophosphane","Cytoxan","Fosfaseron","Frindovyx","Genoxal","Genuxal","Ledoxina","Mitoxan","Neosar","Revimmune","Syklofosfamid","WR 138719","WR- 138719","WR-138719","WR138719",{"type":150,"name":279,"description":280,"armGroupLabels":281,"otherNames":282},"Cytarabine","Given IT or IV",[89,116,121,125,129,133,141],[283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314],".beta.-Cytosine arabinoside","1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-.beta.-D-Arabinofuranosylcytosine","1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-Beta-D-arabinofuranosylcytosine","1.beta.-D-Arabinofuranosylcytosine","2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-","2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-","Alexan","Ara-C","ARA-cell","Arabine","Arabinofuranosylcytosine","Arabinosylcytosine","Aracytidine","Aracytin","Aracytine","Beta-Cytosine Arabinoside","CHX-3311","Cytarabinum","Cytarbel","Cytosar","Cytosine Arabinoside","Cytosine-.beta.-arabinoside","Cytosine-beta-arabinoside","Erpalfa","Starasid","Tarabine PFS","U 19920","U-19920","Udicil","WR-28453",{"type":150,"name":316,"description":186,"armGroupLabels":317,"otherNames":318},"Daunorubicin",[89,116,121,125,129,133,141],[319,320,321,322,323,324],"Daunomycin","Daunorrubicina","DNR","Leukaemomycin C","Rubidomycin","Rubomycin C",{"type":150,"name":326,"description":327,"armGroupLabels":328,"otherNames":329},"Dexamethasone","Given PO or NG or IV",[89,116,121,125,129,133,141],[330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394],"Aacidexam","Adexone","Aknichthol Dexa","Alba-Dex","Alin","Alin Depot","Alin Oftalmico","Amplidermis","Anemul mono","Auricularum","Auxiloson","Baycadron","Baycuten","Baycuten N","Cortidexason","Cortisumman","Decacort","Decadrol","Decadron","Decadron DP","Decalix","Decameth","Decasone R.p.","Dectancyl","Dekacort","Deltafluorene","Deronil","Desamethasone","Desameton","Dexa-Mamallet","Dexa-Rhinosan","Dexa-Scheroson","Dexa-sine","Dexacortal","Dexacortin","Dexafarma","Dexafluorene","Dexalocal","Dexamecortin","Dexameth","Dexamethasone Intensol","Dexamethasonum","Dexamonozon","Dexapos","Dexinoral","Dexone","Dinormon","Dxevo","Fluorodelta","Fortecortin","Gammacorten","Hemady","Hexadecadrol","Hexadrol","LenaDex","Lokalison-F","Loverine","Methylfluorprednisolone","Millicorten","Mymethasone","Orgadrone","Spersadex","TaperDex","Visumetazone","ZoDex",{"type":150,"name":396,"description":186,"armGroupLabels":397,"otherNames":398},"Doxorubicin",[133],[399,400,401,402],"Adriablastin","Hydroxydaunomycin","Hydroxyl Daunorubicin","Hydroxyldaunorubicin",{"type":174,"name":404,"description":405,"armGroupLabels":406,"otherNames":407},"Echocardiography Test","Undergo ECHO",[89,116,121,125,129,133,141,145],[408,409],"EC","Echocardiography",{"type":174,"name":411,"description":412,"armGroupLabels":413,"otherNames":414},"FDG-Positron Emission Tomography","Undergo FDG-PET",[89,116,121,125,129,133,141,145],[415,416,417],"FDG","FDG-PET","FDG-PET Imaging",{"type":150,"name":419,"description":327,"armGroupLabels":420,"otherNames":421},"Leucovorin",[89,116,121,125,129,133,141],[422],"Folinic acid",{"type":150,"name":424,"description":186,"armGroupLabels":425,"otherNames":426},"Levoleucovorin",[89,116,121,125,129,133,141],[427,428,429,430,431,432,433],"CL-307,782","Elvorine, Isovorin, Levofolene, Levorin","Isovorin","Khapzory","L-Leucovorin","Levofolinate","Levofolinic acid",{"type":174,"name":435,"description":436,"armGroupLabels":437,"otherNames":438},"Lumbar Puncture","Undergo lumbar puncture",[89,116,121,125,129,133,141,145],[439,440],"LP","Spinal Tap",{"type":174,"name":442,"description":443,"armGroupLabels":444,"otherNames":445},"Magnetic Resonance Imaging","Undergo MRI",[89,116,121,125,129,133,141,145],[446,447,448,449,450,451,452,453,454,455,456,457,458,459,460],"Magnetic Resonance","Magnetic Resonance Imaging (MRI)","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance \u002F Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","MRIs","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging","sMRI","Structural MRI",{"type":150,"name":462,"description":463,"armGroupLabels":464,"otherNames":465},"Mercaptopurine","Given PO or NG",[89,116,121,125,129,133,141],[466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,497,498,499,500],"3H-Purine-6-thiol","6 MP","6 Thiohypoxanthine","6 Thiopurine","6-Mercaptopurine","6-Mercaptopurine Monohydrate","6-MP","6-Purinethiol","6-Thiopurine","6-Thioxopurine","6H-Purine-6-thione, 1,7-dihydro- (9CI)","7-Mercapto-1,3,4,6-tetrazaindene","Alti-Mercaptopurine","Azathiopurine","Bw 57-323H","Flocofil","Ismipur","Leukerin","Leupurin","Mercaleukim","Mercaleukin","Mercaptina","Mercaptopurinum","Mercapurin","Mern","NCI-C04886","Puri-Nethol","Purimethol","Purine, 6-mercapto-","Purine-6-thiol (8CI)","Purine-6-thiol, monohydrate","Purinethiol","Purinethol","U-4748","WR-2785",{"type":150,"name":502,"description":503,"armGroupLabels":504,"otherNames":505},"Methotrexate","Given IT or IV or PO or NG",[89,116,121,125,129,133,141],[506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541],"Abitrexate","Alpha-Methopterin","Amethopterin","Brimexate","CL 14377","CL-14377","Emtexate","Emthexat","Emthexate","Farmitrexat","Fauldexato","Folex","Folex PFS","Jylamvo","Lantarel","Ledertrexate","Lumexon","Maxtrex","Medsatrexate","Metex","Methoblastin","Methotrexate LPF","Methotrexate Methylaminopterin","Methotrexatum","Metotrexato","Metrotex","Mexate","Mexate-AQ","MTX","Novatrex","Rheumatrex","Texate","Tremetex","Trexeron","Trixilem","WR-19039",{"type":150,"name":543,"description":186,"armGroupLabels":544,"otherNames":545},"Methylprednisolone",[133,145],[546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575],"Adlone","Caberdelta M","DepMedalone","Depo Moderin","Depo-Nisolone","Duralone","Emmetipi","Esametone","Firmacort","Medlone 21","Medrate","Medrol","Medrol Veriderm","Medrone","Mega-Star","Meprolone","Methylprednisolonum","Metilbetasone Solubile","Metrocort","Metypresol","Metysolon","Predni-M-Tablinen","Prednilen","Radilem","Sieropresol","Solpredone","Summicort","Urbason","Veriderm Medrol","Wyacort",{"type":174,"name":577,"description":578,"armGroupLabels":579,"otherNames":580},"Multigated Acquisition Scan","Undergo MUGA",[89,116,121,125,129,133,141,145],[581,582,583,584,585,586,587,588,589,590,591,592,593],"Blood Pool Scan","Equilibrium Radionuclide Angiography","Gated Blood Pool Imaging","Gated Heart Pool Scan","MUGA","MUGA Scan","Multi-Gated Acquisition Scan","Radionuclide Ventriculogram Scan","Radionuclide Ventriculography","RNV Scan","RNVG","SYMA Scanning","Synchronized Multigated Acquisition Scanning",{"type":150,"name":595,"description":463,"armGroupLabels":596,"otherNames":597},"Prednisolone",[133,145],[598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650],"(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione",".delta.1-Hydrocortisone","Adnisolone","Aprednislon","Capsoid","Cortalone","Cortisolone","Dacortin H","Decaprednil","Decortin H","Delta(1)Hydrocortisone","Delta- Cortef","Delta-Cortef","Delta-Diona","Delta-F","Delta-Phoricol","Delta1-dehydro-hydrocortisone","Deltacortril","Deltahydrocortisone","Deltasolone","Deltidrosol","Dhasolone","Di-Adreson-F","Dontisolon D","Estilsona","Fisopred","Frisolona","Gupisone","Hostacortin H","Hydeltra","Hydeltrasol","Klismacort","Kuhlprednon","Lenisolone","Lepi-Cortinolo","Linola-H N","Linola-H-Fett N","Longiprednil","Metacortandralone","Meti Derm","Meticortelone","Opredsone","Panafcortelone","Precortisyl","Pred-Clysma","Predeltilone","Predni-Coelin","Predni-Helvacort","Prednicortelone","Prednisolonum","Prelone","Prenilone","Sterane",{"type":150,"name":652,"description":463,"armGroupLabels":653,"otherNames":654},"Prednisone",[133,145],[655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680,681,682,683,684,685,686,687,688,689,690,691,692,693,694,695,696],".delta.1-Cortisone","1, 2-Dehydrocortisone","Adasone","Cortancyl","Dacortin","DeCortin","Decortisyl","Decorton","Delta 1-Cortisone","Delta-Dome","Deltacortene","Deltacortisone","Deltadehydrocortisone","Deltasone","Deltison","Deltra","Econosone","Lisacort","Meprosona-F","Metacortandracin","Meticorten","Ofisolona","Orasone","Panafcort","Panasol-S","Paracort","Perrigo Prednisone","PRED","Predicor","Predicorten","Prednicen-M","Prednicort","Prednidib","Prednilonga","Predniment","Prednisone Intensol","Prednisonum","Prednitone","Promifen","Rayos","Servisone","SK-Prednisone",{"type":150,"name":698,"description":699,"armGroupLabels":700,"otherNames":701},"Therapeutic Hydrocortisone","Given IT",[89,116,121,125,129,133,141],[702,703,704,705,706,707,708,709,710,711,712,713,714,715,716,717,718,719,720,721,722,723,724],"Aeroseb-HC","Barseb HC","Barseb-HC","Cetacort","Cort-Dome","Cortef","Cortenema","Cortifan","Cortisol","Cortispray","Cortril","Dermacort","Domolene","Eldecort","Hautosone","Heb-Cort","Hydrocortisone","Hydrocortone","Hytone","Komed-HC","Nutracort","Proctocort","Rectoid",{"type":150,"name":726,"description":463,"armGroupLabels":727,"otherNames":728},"Thioguanine",[89,116,121,125,129,133,141],[729,730,731,732,733,734,735,736,737,738,739,740,741,742,743,744,745,746,747,748,749,750,751,752],"2-Amino 6MP","2-Amino-1,7-dihydro-6H-purine-6-thione","2-Amino-6-mercaptopurine","2-Amino-6-purinethiol","2-Aminopurin-6-thiol","2-Aminopurine-6(1H)-thione","2-Aminopurine-6-thiol","2-Aminopurine-6-thiol Hemihydrate","2-Mercapto-6-aminopurine","6-Amino-2-mercaptopurine","6-Mercapto-2-aminopurine","6-Mercaptoguanine","6-TG","6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)","BW 5071","Lanvis","Tabloid","Thioguanine Hemihydrate","Thioguanine Hydrate","Tioguanin","Tioguanine","Wellcome U3B","WR-1141","X 27",{"type":150,"name":754,"description":463,"armGroupLabels":755,"otherNames":756},"Venetoclax",[116,121,125,129,141],[757,758,759,760,761,762,763,764,765,766],"ABT 199","ABT-0199","ABT-199","ABT199","GDC 0199","GDC-0199","GDC0199","RG7601","Venclexta","Venclyxto",{"type":150,"name":768,"description":186,"armGroupLabels":769,"otherNames":770},"Vincristine",[89,116,121,125,129,133,141],[771,772,773,774],"LCR","Leurocristine","VCR","Vincrystine",[776],{"name":777,"affiliation":778,"role":779},"Erin H Breese","Children's Oncology Group","PRINCIPAL_INVESTIGATOR",[781,803,819,834,849,864,878,893,905,920,934,948,964,975,990,1006,1022,1037,1052,1064,1078,1093,1105,1114,1128,1143,1158,1172,1188,1203,1219,1234,1246,1260,1272,1287,1301,1316,1332,1347,1362,1377,1389,1405,1420,1432,1447,1462,1477,1492,1504,1519,1534,1550,1565,1576,1591,1607,1623,1638,1652,1666,1681,1696,1711,1725,1738,1749,1759,1773,1787,1802,1816,1832,1846,1860,1875,1889,1905,1920,1935,1949,1963,1978,1994,2010,2025,2039,2054,2069,2084,2100,2112,2128,2143,2158,2172,2183,2199,2214,2228,2240,2255,2270,2285,2300,2312,2328,2343,2358,2373,2388,2403,2419,2434],{"facility":782,"status":783,"city":784,"state":785,"zip":786,"country":787,"countryCode":788,"cosmosGeoPoint":789,"geoPoint":794,"contacts":795},"Children's Hospital of Alabama","RECRUITING","Birmingham","Alabama","35233","United States","US",{"type":790,"coordinates":791},"Point",[792,793],-86.80249,33.52066,{"lat":793,"lon":792},[796,801],{"name":797,"role":798,"phone":799,"phoneExt":82,"email":800},"Site Public Contact","CONTACT","205-638-9285","oncologyresearch@peds.uab.edu",{"name":802,"role":779,"phone":82,"phoneExt":82,"email":82},"Matthew A. Kutny",{"facility":804,"status":783,"city":805,"state":806,"zip":807,"country":787,"countryCode":788,"cosmosGeoPoint":808,"geoPoint":812,"contacts":813},"Providence Alaska Medical Center","Anchorage","Alaska","99508",{"type":790,"coordinates":809},[810,811],-149.90028,61.21806,{"lat":811,"lon":810},[814,817],{"name":797,"role":798,"phone":815,"phoneExt":82,"email":816},"907-212-6871","AKPAMC.OncologyResearchSupport@providence.org",{"name":818,"role":779,"phone":82,"phoneExt":82,"email":82},"Brenda J. Wittman",{"facility":820,"status":783,"city":821,"state":822,"zip":823,"country":787,"countryCode":788,"cosmosGeoPoint":824,"geoPoint":828,"contacts":829},"Banner Children's at Desert","Mesa","Arizona","85202",{"type":790,"coordinates":825},[826,827],-111.82264,33.42227,{"lat":827,"lon":826},[830,832],{"name":797,"role":798,"phone":831,"phoneExt":82,"email":82},"480-412-3100",{"name":833,"role":779,"phone":82,"phoneExt":82,"email":82},"Joseph C. Torkildson",{"facility":835,"status":783,"city":836,"state":837,"zip":838,"country":787,"countryCode":788,"cosmosGeoPoint":839,"geoPoint":843,"contacts":844},"Arkansas Children's Hospital","Little Rock","Arkansas","72202-3591",{"type":790,"coordinates":840},[841,842],-92.28959,34.74648,{"lat":842,"lon":841},[845,847],{"name":797,"role":798,"phone":846,"phoneExt":82,"email":82},"501-364-7373",{"name":848,"role":779,"phone":82,"phoneExt":82,"email":82},"Michael W. Bishop",{"facility":850,"status":783,"city":851,"state":852,"zip":853,"country":787,"countryCode":788,"cosmosGeoPoint":854,"geoPoint":858,"contacts":859},"Loma Linda University Medical Center","Loma Linda","California","92354",{"type":790,"coordinates":855},[856,857],-117.26115,34.04835,{"lat":857,"lon":856},[860,862],{"name":797,"role":798,"phone":861,"phoneExt":82,"email":82},"909-558-4050",{"name":863,"role":779,"phone":82,"phoneExt":82,"email":82},"Albert Kheradpour",{"facility":865,"status":783,"city":866,"state":852,"zip":867,"country":787,"countryCode":788,"cosmosGeoPoint":868,"geoPoint":872,"contacts":873},"Miller Children's and Women's Hospital Long Beach","Long Beach","90806",{"type":790,"coordinates":869},[870,871],-118.18923,33.76696,{"lat":871,"lon":870},[874,876],{"name":797,"role":798,"phone":875,"phoneExt":82,"email":82},"562-933-5600",{"name":877,"role":779,"phone":82,"phoneExt":82,"email":82},"Jacqueline N. Casillas",{"facility":879,"status":783,"city":880,"state":852,"zip":881,"country":787,"countryCode":788,"cosmosGeoPoint":882,"geoPoint":886,"contacts":887},"UCSF Benioff Children's Hospital Oakland","Oakland","94609",{"type":790,"coordinates":883},[884,885],-122.2708,37.80437,{"lat":885,"lon":884},[888,891],{"name":797,"role":798,"phone":889,"phoneExt":82,"email":890},"510-428-3264","PedOncRschOAK@ucsf.edu",{"name":892,"role":779,"phone":82,"phoneExt":82,"email":82},"Anya Levinson",{"facility":894,"status":783,"city":880,"state":852,"zip":895,"country":787,"countryCode":788,"cosmosGeoPoint":896,"geoPoint":898,"contacts":899},"Kaiser Permanente-Oakland","94611",{"type":790,"coordinates":897},[884,885],{"lat":885,"lon":884},[900,903],{"name":797,"role":798,"phone":901,"phoneExt":82,"email":902},"877-642-4691","Kpoct@kp.org",{"name":904,"role":779,"phone":82,"phoneExt":82,"email":82},"Aarati V. Rao",{"facility":906,"status":783,"city":907,"state":852,"zip":908,"country":787,"countryCode":788,"cosmosGeoPoint":909,"geoPoint":913,"contacts":914},"Children's Hospital of Orange County","Orange","92868",{"type":790,"coordinates":910},[911,912],-117.85311,33.78779,{"lat":912,"lon":911},[915,918],{"name":797,"role":798,"phone":916,"phoneExt":82,"email":917},"714-509-8646","oncresearch@choc.org",{"name":919,"role":779,"phone":82,"phoneExt":82,"email":82},"Elyssa M. Rubin",{"facility":921,"status":783,"city":922,"state":852,"zip":923,"country":787,"countryCode":788,"cosmosGeoPoint":924,"geoPoint":928,"contacts":929},"University of California Davis Comprehensive Cancer Center","Sacramento","95817",{"type":790,"coordinates":925},[926,927],-121.4944,38.58157,{"lat":927,"lon":926},[930,932],{"name":797,"role":798,"phone":931,"phoneExt":82,"email":82},"916-734-3089",{"name":933,"role":779,"phone":82,"phoneExt":82,"email":82},"Marcio H. Malogolowkin",{"facility":935,"status":783,"city":936,"state":852,"zip":937,"country":787,"countryCode":788,"cosmosGeoPoint":938,"geoPoint":942,"contacts":943},"UCSF Medical Center-Mission Bay","San Francisco","94158",{"type":790,"coordinates":939},[940,941],-122.41942,37.77493,{"lat":941,"lon":940},[944,947],{"name":797,"role":798,"phone":945,"phoneExt":82,"email":946},"877-827-3222","cancertrials@ucsf.edu",{"name":892,"role":779,"phone":82,"phoneExt":82,"email":82},{"facility":949,"status":783,"city":950,"state":951,"zip":952,"country":787,"countryCode":788,"cosmosGeoPoint":953,"geoPoint":957,"contacts":958},"Children's Hospital Colorado","Aurora","Colorado","80045",{"type":790,"coordinates":954},[955,956],-104.83192,39.72943,{"lat":956,"lon":955},[959,962],{"name":797,"role":798,"phone":960,"phoneExt":82,"email":961},"303-764-5056","josh.b.gordon@nsmtp.kp.org",{"name":963,"role":779,"phone":82,"phoneExt":82,"email":82},"Kelly E. Faulk",{"facility":965,"status":966,"city":967,"state":968,"zip":969,"country":787,"countryCode":788,"cosmosGeoPoint":970,"geoPoint":974,"contacts":82},"Connecticut Children's Medical Center","SUSPENDED","Hartford","Connecticut","06106",{"type":790,"coordinates":971},[972,973],-72.68509,41.76371,{"lat":973,"lon":972},{"facility":976,"status":783,"city":977,"state":968,"zip":978,"country":787,"countryCode":788,"cosmosGeoPoint":979,"geoPoint":983,"contacts":984},"Yale University","New Haven","06520",{"type":790,"coordinates":980},[981,982],-72.92816,41.30815,{"lat":982,"lon":981},[985,988],{"name":797,"role":798,"phone":986,"phoneExt":82,"email":987},"203-785-5702","canceranswers@yale.edu",{"name":989,"role":779,"phone":82,"phoneExt":82,"email":82},"Farzana Pashankar",{"facility":991,"status":783,"city":992,"state":993,"zip":994,"country":787,"countryCode":788,"cosmosGeoPoint":995,"geoPoint":999,"contacts":1000},"Alfred I duPont Hospital for Children","Wilmington","Delaware","19803",{"type":790,"coordinates":996},[997,998],-75.54659,39.74595,{"lat":998,"lon":997},[1001,1004],{"name":797,"role":798,"phone":1002,"phoneExt":82,"email":1003},"302-651-5572","Allison.bruce@nemours.org",{"name":1005,"role":779,"phone":82,"phoneExt":82,"email":82},"Emi H. Caywood",{"facility":1007,"status":783,"city":1008,"state":1009,"zip":1010,"country":787,"countryCode":788,"cosmosGeoPoint":1011,"geoPoint":1015,"contacts":1016},"Children's National Medical Center","Washington D.C.","District of Columbia","20010",{"type":790,"coordinates":1012},[1013,1014],-77.03637,38.89511,{"lat":1014,"lon":1013},[1017,1020],{"name":797,"role":798,"phone":1018,"phoneExt":82,"email":1019},"202-476-2800","OncCRC_OnCall@childrensnational.org",{"name":1021,"role":779,"phone":82,"phoneExt":82,"email":82},"Jeffrey S. Dome",{"facility":1023,"status":783,"city":1024,"state":1025,"zip":1026,"country":787,"countryCode":788,"cosmosGeoPoint":1027,"geoPoint":1031,"contacts":1032},"UF Health Cancer Institute - Gainesville","Gainesville","Florida","32610",{"type":790,"coordinates":1028},[1029,1030],-82.32483,29.65163,{"lat":1030,"lon":1029},[1033,1035],{"name":797,"role":798,"phone":1034,"phoneExt":82,"email":82},"352-273-8010",{"name":1036,"role":779,"phone":82,"phoneExt":82,"email":82},"Brian Stover",{"facility":1038,"status":783,"city":1039,"state":1025,"zip":1040,"country":787,"countryCode":788,"cosmosGeoPoint":1041,"geoPoint":1045,"contacts":1046},"Memorial Regional Hospital\u002FJoe DiMaggio Children's Hospital","Hollywood","33021",{"type":790,"coordinates":1042},[1043,1044],-80.14949,26.0112,{"lat":1044,"lon":1043},[1047,1050],{"name":797,"role":798,"phone":1048,"phoneExt":82,"email":1049},"954-265-1847","OHR@mhs.net",{"name":1051,"role":779,"phone":82,"phoneExt":82,"email":82},"Iftikhar Hanif",{"facility":1053,"status":783,"city":1054,"state":1025,"zip":1055,"country":787,"countryCode":788,"cosmosGeoPoint":1056,"geoPoint":1060,"contacts":1061},"Nemours Children's Clinic-Jacksonville","Jacksonville","32207",{"type":790,"coordinates":1057},[1058,1059],-81.65565,30.33218,{"lat":1059,"lon":1058},[1062,1063],{"name":797,"role":798,"phone":1002,"phoneExt":82,"email":1003},{"name":1005,"role":779,"phone":82,"phoneExt":82,"email":82},{"facility":1065,"status":783,"city":1066,"state":1025,"zip":1067,"country":787,"countryCode":788,"cosmosGeoPoint":1068,"geoPoint":1072,"contacts":1073},"University of Miami Miller School of Medicine-Sylvester Cancer Center","Miami","33136",{"type":790,"coordinates":1069},[1070,1071],-80.19366,25.77427,{"lat":1071,"lon":1070},[1074,1076],{"name":797,"role":798,"phone":1075,"phoneExt":82,"email":82},"305-243-2647",{"name":1077,"role":779,"phone":82,"phoneExt":82,"email":82},"Julio C. Barredo",{"facility":1079,"status":783,"city":1080,"state":1025,"zip":1081,"country":787,"countryCode":788,"cosmosGeoPoint":1082,"geoPoint":1086,"contacts":1087},"AdventHealth Orlando","Orlando","32803",{"type":790,"coordinates":1083},[1084,1085],-81.37924,28.53834,{"lat":1085,"lon":1084},[1088,1091],{"name":797,"role":798,"phone":1089,"phoneExt":82,"email":1090},"407-303-2090","FH.Cancer.Research@flhosp.org",{"name":1092,"role":779,"phone":82,"phoneExt":82,"email":82},"Fouad M. Hajjar",{"facility":1094,"status":783,"city":1080,"state":1025,"zip":1095,"country":787,"countryCode":788,"cosmosGeoPoint":1096,"geoPoint":1098,"contacts":1099},"Arnold Palmer Hospital for Children","32806",{"type":790,"coordinates":1097},[1084,1085],{"lat":1085,"lon":1084},[1100,1103],{"name":797,"role":798,"phone":1101,"phoneExt":82,"email":1102},"321-841-5357","Jennifer.spinelli@orlandohealth.com",{"name":1104,"role":779,"phone":82,"phoneExt":82,"email":82},"Zhongbo Hu",{"facility":1106,"status":783,"city":1080,"state":1025,"zip":1107,"country":787,"countryCode":788,"cosmosGeoPoint":1108,"geoPoint":1110,"contacts":1111},"Nemours Children's Hospital","32827",{"type":790,"coordinates":1109},[1084,1085],{"lat":1085,"lon":1084},[1112,1113],{"name":797,"role":798,"phone":1002,"phoneExt":82,"email":1003},{"name":1005,"role":779,"phone":82,"phoneExt":82,"email":82},{"facility":1115,"status":783,"city":1116,"state":1025,"zip":1117,"country":787,"countryCode":788,"cosmosGeoPoint":1118,"geoPoint":1122,"contacts":1123},"Nemours Children's Clinic - Pensacola","Pensacola","32504",{"type":790,"coordinates":1119},[1120,1121],-87.21691,30.42131,{"lat":1121,"lon":1120},[1124,1126],{"name":797,"role":798,"phone":82,"phoneExt":82,"email":1125},"helpdesk@childrensoncologygroup.org",{"name":1127,"role":779,"phone":82,"phoneExt":82,"email":82},"Jeffrey H. Schwartz",{"facility":1129,"status":783,"city":1130,"state":1025,"zip":1131,"country":787,"countryCode":788,"cosmosGeoPoint":1132,"geoPoint":1136,"contacts":1137},"Johns Hopkins All Children's Hospital","St. Petersburg","33701",{"type":790,"coordinates":1133},[1134,1135],-82.67927,27.77086,{"lat":1135,"lon":1134},[1138,1141],{"name":797,"role":798,"phone":1139,"phoneExt":82,"email":1140},"727-767-4784","Ashley.Repp@jhmi.edu",{"name":1142,"role":779,"phone":82,"phoneExt":82,"email":82},"Jennifer B. Dean",{"facility":1144,"status":783,"city":1145,"state":1025,"zip":1146,"country":787,"countryCode":788,"cosmosGeoPoint":1147,"geoPoint":1151,"contacts":1152},"Saint Joseph's Hospital\u002FChildren's Hospital-Tampa","Tampa","33607",{"type":790,"coordinates":1148},[1149,1150],-82.45843,27.94752,{"lat":1150,"lon":1149},[1153,1156],{"name":797,"role":798,"phone":1154,"phoneExt":82,"email":1155},"813-357-0849","jennifer.manns@baycare.org",{"name":1157,"role":779,"phone":82,"phoneExt":82,"email":82},"Don E. Eslin",{"facility":1159,"status":783,"city":1160,"state":1025,"zip":1161,"country":787,"countryCode":788,"cosmosGeoPoint":1162,"geoPoint":1166,"contacts":1167},"Saint Mary's Medical Center","West Palm Beach","33407",{"type":790,"coordinates":1163},[1164,1165],-80.05337,26.71534,{"lat":1165,"lon":1164},[1168,1170],{"name":797,"role":798,"phone":1169,"phoneExt":82,"email":82},"561-822-4745",{"name":1171,"role":779,"phone":82,"phoneExt":82,"email":82},"Matthew D. Ramirez",{"facility":1173,"status":783,"city":1174,"state":1175,"zip":1176,"country":787,"countryCode":788,"cosmosGeoPoint":1177,"geoPoint":1181,"contacts":1182},"Children's Healthcare of Atlanta - Arthur M Blank Hospital","Atlanta","Georgia","30329",{"type":790,"coordinates":1178},[1179,1180],-84.38798,33.749,{"lat":1180,"lon":1179},[1183,1186],{"name":797,"role":798,"phone":1184,"phoneExt":82,"email":1185},"404-785-0232","Olivia.Floyd@choa.org",{"name":1187,"role":779,"phone":82,"phoneExt":82,"email":82},"Melinda G. Pauly",{"facility":1189,"status":783,"city":1190,"state":1191,"zip":1192,"country":787,"countryCode":788,"cosmosGeoPoint":1193,"geoPoint":1197,"contacts":1198},"Kapiolani Medical Center for Women and Children","Honolulu","Hawaii","96826",{"type":790,"coordinates":1194},[1195,1196],-157.85833,21.30694,{"lat":1196,"lon":1195},[1199,1201],{"name":797,"role":798,"phone":1200,"phoneExt":82,"email":82},"808-983-6090",{"name":1202,"role":779,"phone":82,"phoneExt":82,"email":82},"Wade T. Kyono",{"facility":1204,"status":783,"city":1205,"state":1206,"zip":1207,"country":787,"countryCode":788,"cosmosGeoPoint":1208,"geoPoint":1212,"contacts":1213},"Saint Luke's Cancer Institute - Boise","Boise","Idaho","83712",{"type":790,"coordinates":1209},[1210,1211],-116.20345,43.6135,{"lat":1211,"lon":1210},[1214,1217],{"name":797,"role":798,"phone":1215,"phoneExt":82,"email":1216},"208-381-2774","eslinget@slhs.org",{"name":1218,"role":779,"phone":82,"phoneExt":82,"email":82},"Martha M. Pacheco",{"facility":1220,"status":783,"city":1221,"state":1222,"zip":1223,"country":787,"countryCode":788,"cosmosGeoPoint":1224,"geoPoint":1228,"contacts":1229},"Lurie Children's Hospital-Chicago","Chicago","Illinois","60611",{"type":790,"coordinates":1225},[1226,1227],-87.65005,41.85003,{"lat":1227,"lon":1226},[1230,1232],{"name":797,"role":798,"phone":1231,"phoneExt":82,"email":82},"773-880-4562",{"name":1233,"role":779,"phone":82,"phoneExt":82,"email":82},"Sara Zarnegar-Lumley",{"facility":1235,"status":783,"city":1221,"state":1222,"zip":1236,"country":787,"countryCode":788,"cosmosGeoPoint":1237,"geoPoint":1239,"contacts":1240},"University of Chicago Comprehensive Cancer Center","60637",{"type":790,"coordinates":1238},[1226,1227],{"lat":1227,"lon":1226},[1241,1244],{"name":797,"role":798,"phone":1242,"phoneExt":82,"email":1243},"773-702-8222","cancerclinicaltrials@bsd.uchicago.edu",{"name":1245,"role":779,"phone":82,"phoneExt":82,"email":82},"Gabrielle Lapping-Carr",{"facility":1247,"status":783,"city":1248,"state":1222,"zip":1249,"country":787,"countryCode":788,"cosmosGeoPoint":1250,"geoPoint":1254,"contacts":1255},"Advocate Children's Hospital-Oak Lawn","Oak Lawn","60453",{"type":790,"coordinates":1251},[1252,1253],-87.75811,41.71087,{"lat":1253,"lon":1252},[1256,1258],{"name":797,"role":798,"phone":1257,"phoneExt":82,"email":82},"847-723-7570",{"name":1259,"role":779,"phone":82,"phoneExt":82,"email":82},"Rebecca E. McFall",{"facility":1261,"status":783,"city":1262,"state":1222,"zip":1263,"country":787,"countryCode":788,"cosmosGeoPoint":1264,"geoPoint":1268,"contacts":1269},"Advocate Children's Hospital-Park Ridge","Park Ridge","60068",{"type":790,"coordinates":1265},[1266,1267],-87.84062,42.01114,{"lat":1267,"lon":1266},[1270,1271],{"name":797,"role":798,"phone":82,"phoneExt":82,"email":1125},{"name":1259,"role":779,"phone":82,"phoneExt":82,"email":82},{"facility":1273,"status":783,"city":1274,"state":1222,"zip":1275,"country":787,"countryCode":788,"cosmosGeoPoint":1276,"geoPoint":1280,"contacts":1281},"OSF Children's Hospital of Illinois","Peoria","61637",{"type":790,"coordinates":1277},[1278,1279],-89.58899,40.69365,{"lat":1279,"lon":1278},[1282,1285],{"name":797,"role":798,"phone":1283,"phoneExt":82,"email":1284},"309-624-4945","ChildrensHospitalofIllinois@osfhealthcare.org",{"name":1286,"role":779,"phone":82,"phoneExt":82,"email":82},"Prerna Kumar",{"facility":1288,"status":783,"city":1289,"state":1222,"zip":1290,"country":787,"countryCode":788,"cosmosGeoPoint":1291,"geoPoint":1295,"contacts":1296},"Southern Illinois University School of Medicine","Springfield","62702",{"type":790,"coordinates":1292},[1293,1294],-89.64371,39.80172,{"lat":1294,"lon":1293},[1297,1299],{"name":797,"role":798,"phone":1298,"phoneExt":82,"email":82},"217-545-7929",{"name":1300,"role":779,"phone":82,"phoneExt":82,"email":82},"Gregory P. Brandt",{"facility":1302,"status":783,"city":1303,"state":1304,"zip":1305,"country":787,"countryCode":788,"cosmosGeoPoint":1306,"geoPoint":1310,"contacts":1311},"Riley Hospital for Children","Indianapolis","Indiana","46202",{"type":790,"coordinates":1307},[1308,1309],-86.15804,39.76838,{"lat":1309,"lon":1308},[1312,1314],{"name":797,"role":798,"phone":1313,"phoneExt":82,"email":82},"800-248-1199",{"name":1315,"role":779,"phone":82,"phoneExt":82,"email":82},"Amanda Saraf",{"facility":1317,"status":783,"city":1318,"state":1319,"zip":1320,"country":787,"countryCode":788,"cosmosGeoPoint":1321,"geoPoint":1325,"contacts":1326},"Blank Children's Hospital","Des Moines","Iowa","50309",{"type":790,"coordinates":1322},[1323,1324],-93.60911,41.60054,{"lat":1324,"lon":1323},[1327,1330],{"name":797,"role":798,"phone":1328,"phoneExt":82,"email":1329},"515-241-8912","samantha.mallory@unitypoint.org",{"name":1331,"role":779,"phone":82,"phoneExt":82,"email":82},"Samantha L. Mallory",{"facility":1333,"status":783,"city":1334,"state":1335,"zip":1336,"country":787,"countryCode":788,"cosmosGeoPoint":1337,"geoPoint":1341,"contacts":1342},"University of Kentucky\u002FMarkey Cancer Center","Lexington","Kentucky","40536",{"type":790,"coordinates":1338},[1339,1340],-84.47772,37.98869,{"lat":1340,"lon":1339},[1343,1345],{"name":797,"role":798,"phone":1344,"phoneExt":82,"email":82},"859-257-3379",{"name":1346,"role":779,"phone":82,"phoneExt":82,"email":82},"James T. Badgett",{"facility":1348,"status":783,"city":1349,"state":1335,"zip":1350,"country":787,"countryCode":788,"cosmosGeoPoint":1351,"geoPoint":1355,"contacts":1356},"Norton Children's Hospital","Louisville","40202",{"type":790,"coordinates":1352},[1353,1354],-85.75941,38.25424,{"lat":1354,"lon":1353},[1357,1360],{"name":797,"role":798,"phone":1358,"phoneExt":82,"email":1359},"502-629-5500","CancerResource@nortonhealthcare.org",{"name":1361,"role":779,"phone":82,"phoneExt":82,"email":82},"Michael J. Ferguson",{"facility":1363,"status":783,"city":1364,"state":1365,"zip":1366,"country":787,"countryCode":788,"cosmosGeoPoint":1367,"geoPoint":1371,"contacts":1372},"Children's Hospital New Orleans","New Orleans","Louisiana","70118",{"type":790,"coordinates":1368},[1369,1370],-90.07507,29.95465,{"lat":1370,"lon":1369},[1373,1375],{"name":797,"role":798,"phone":1374,"phoneExt":82,"email":82},"504-894-5377",{"name":1376,"role":779,"phone":82,"phoneExt":82,"email":82},"Maria C. Velez-Yanguas",{"facility":1378,"status":783,"city":1364,"state":1365,"zip":1379,"country":787,"countryCode":788,"cosmosGeoPoint":1380,"geoPoint":1382,"contacts":1383},"Ochsner Medical Center Jefferson","70121",{"type":790,"coordinates":1381},[1369,1370],{"lat":1370,"lon":1369},[1384,1387],{"name":797,"role":798,"phone":1385,"phoneExt":82,"email":1386},"504-842-8084","Elisemarie.curry@ochsner.org",{"name":1388,"role":779,"phone":82,"phoneExt":82,"email":82},"Craig Lotterman",{"facility":1390,"status":783,"city":1391,"state":1392,"zip":1393,"country":787,"countryCode":788,"cosmosGeoPoint":1394,"geoPoint":1398,"contacts":1399},"Maine Children's Cancer Program","Scarborough","Maine","04074",{"type":790,"coordinates":1395},[1396,1397],-70.32172,43.57814,{"lat":1397,"lon":1396},[1400,1403],{"name":797,"role":798,"phone":1401,"phoneExt":82,"email":1402},"207-396-8670","clinicalresearch@mainehealth.org",{"name":1404,"role":779,"phone":82,"phoneExt":82,"email":82},"Sei-Gyung K. Sze",{"facility":1406,"status":783,"city":1407,"state":1408,"zip":1409,"country":787,"countryCode":788,"cosmosGeoPoint":1410,"geoPoint":1414,"contacts":1415},"Sinai Hospital of Baltimore","Baltimore","Maryland","21215",{"type":790,"coordinates":1411},[1412,1413],-76.61219,39.29038,{"lat":1413,"lon":1412},[1416,1418],{"name":797,"role":798,"phone":1417,"phoneExt":82,"email":82},"410-601-9083",{"name":1419,"role":779,"phone":82,"phoneExt":82,"email":82},"Jason M. Fixler",{"facility":1421,"status":783,"city":1407,"state":1408,"zip":1422,"country":787,"countryCode":788,"cosmosGeoPoint":1423,"geoPoint":1425,"contacts":1426},"Johns Hopkins University\u002FSidney Kimmel Cancer Center","21287",{"type":790,"coordinates":1424},[1412,1413],{"lat":1413,"lon":1412},[1427,1430],{"name":797,"role":798,"phone":1428,"phoneExt":82,"email":1429},"410-955-8804","jhcccro@jhmi.edu",{"name":1431,"role":779,"phone":82,"phoneExt":82,"email":82},"Stacy L. Cooper",{"facility":1433,"status":783,"city":1434,"state":1435,"zip":1436,"country":787,"countryCode":788,"cosmosGeoPoint":1437,"geoPoint":1441,"contacts":1442},"Dana-Farber Cancer Institute","Boston","Massachusetts","02215",{"type":790,"coordinates":1438},[1439,1440],-71.05977,42.35843,{"lat":1440,"lon":1439},[1443,1445],{"name":797,"role":798,"phone":1444,"phoneExt":82,"email":82},"877-442-3324",{"name":1446,"role":779,"phone":82,"phoneExt":82,"email":82},"Melissa A. Burns",{"facility":1448,"status":783,"city":1449,"state":1435,"zip":1450,"country":787,"countryCode":788,"cosmosGeoPoint":1451,"geoPoint":1455,"contacts":1456},"UMass Memorial Medical Center - University Campus","Worcester","01655",{"type":790,"coordinates":1452},[1453,1454],-71.80229,42.26259,{"lat":1454,"lon":1453},[1457,1460],{"name":797,"role":798,"phone":1458,"phoneExt":82,"email":1459},"508-856-3216","cancer.research@umassmed.edu",{"name":1461,"role":779,"phone":82,"phoneExt":82,"email":82},"Stefanie R. Lowas",{"facility":1463,"status":783,"city":1464,"state":1465,"zip":1466,"country":787,"countryCode":788,"cosmosGeoPoint":1467,"geoPoint":1471,"contacts":1472},"C S Mott Children's Hospital","Ann Arbor","Michigan","48109",{"type":790,"coordinates":1468},[1469,1470],-83.74088,42.27756,{"lat":1470,"lon":1469},[1473,1475],{"name":797,"role":798,"phone":1474,"phoneExt":82,"email":82},"800-865-1125",{"name":1476,"role":779,"phone":82,"phoneExt":82,"email":82},"Joshua W. Goldman",{"facility":1478,"status":783,"city":1479,"state":1465,"zip":1480,"country":787,"countryCode":788,"cosmosGeoPoint":1481,"geoPoint":1485,"contacts":1486},"Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital","Grand Rapids","49503",{"type":790,"coordinates":1482},[1483,1484],-85.66809,42.96336,{"lat":1484,"lon":1483},[1487,1490],{"name":797,"role":798,"phone":1488,"phoneExt":82,"email":1489},"616-391-1230","crcwm-regulatory@crcwm.org",{"name":1491,"role":779,"phone":82,"phoneExt":82,"email":82},"Kathleen Y. Butler",{"facility":1493,"status":783,"city":1494,"state":1465,"zip":1495,"country":787,"countryCode":788,"cosmosGeoPoint":1496,"geoPoint":1500,"contacts":1501},"Bronson Methodist Hospital","Kalamazoo","49007",{"type":790,"coordinates":1497},[1498,1499],-85.58723,42.29171,{"lat":1499,"lon":1498},[1502,1503],{"name":797,"role":798,"phone":1488,"phoneExt":82,"email":1489},{"name":1491,"role":779,"phone":82,"phoneExt":82,"email":82},{"facility":1505,"status":783,"city":1506,"state":1507,"zip":1508,"country":787,"countryCode":788,"cosmosGeoPoint":1509,"geoPoint":1513,"contacts":1514},"University of Minnesota\u002FMasonic Cancer Center","Minneapolis","Minnesota","55455",{"type":790,"coordinates":1510},[1511,1512],-93.26384,44.97997,{"lat":1512,"lon":1511},[1515,1517],{"name":797,"role":798,"phone":1516,"phoneExt":82,"email":82},"612-624-2620",{"name":1518,"role":779,"phone":82,"phoneExt":82,"email":82},"Peter M. Gordon",{"facility":1520,"status":783,"city":1521,"state":1522,"zip":1523,"country":787,"countryCode":788,"cosmosGeoPoint":1524,"geoPoint":1528,"contacts":1529},"University of Mississippi Medical Center","Jackson","Mississippi","39216",{"type":790,"coordinates":1525},[1526,1527],-90.18481,32.29876,{"lat":1527,"lon":1526},[1530,1532],{"name":797,"role":798,"phone":1531,"phoneExt":82,"email":82},"601-815-6700",{"name":1533,"role":779,"phone":82,"phoneExt":82,"email":82},"Amanda Strobel",{"facility":1535,"status":783,"city":1536,"state":1537,"zip":1538,"country":787,"countryCode":788,"cosmosGeoPoint":1539,"geoPoint":1543,"contacts":1544},"Children's Mercy Hospitals and Clinics","Kansas City","Missouri","64108",{"type":790,"coordinates":1540},[1541,1542],-94.57857,39.09973,{"lat":1542,"lon":1541},[1545,1548],{"name":797,"role":798,"phone":1546,"phoneExt":82,"email":1547},"816-302-6808","COGResearchGroup@cmh.edu",{"name":1549,"role":779,"phone":82,"phoneExt":82,"email":82},"Keith J. August",{"facility":1551,"status":783,"city":1552,"state":1537,"zip":1553,"country":787,"countryCode":788,"cosmosGeoPoint":1554,"geoPoint":1558,"contacts":1559},"Washington University School of Medicine","St Louis","63110",{"type":790,"coordinates":1555},[1556,1557],-90.19789,38.62727,{"lat":1557,"lon":1556},[1560,1563],{"name":797,"role":798,"phone":1561,"phoneExt":82,"email":1562},"800-600-3606","info@siteman.wustl.edu",{"name":1564,"role":779,"phone":82,"phoneExt":82,"email":82},"Laura G. Schuettpelz",{"facility":1566,"status":783,"city":1552,"state":1537,"zip":1567,"country":787,"countryCode":788,"cosmosGeoPoint":1568,"geoPoint":1570,"contacts":1571},"Mercy Hospital Saint Louis","63141",{"type":790,"coordinates":1569},[1556,1557],{"lat":1557,"lon":1556},[1572,1574],{"name":797,"role":798,"phone":1573,"phoneExt":82,"email":82},"314-251-7066",{"name":1575,"role":779,"phone":82,"phoneExt":82,"email":82},"Robin D. Hanson",{"facility":1577,"status":783,"city":1578,"state":1579,"zip":1580,"country":787,"countryCode":788,"cosmosGeoPoint":1581,"geoPoint":1585,"contacts":1586},"Children's Hospital and Medical Center of Omaha","Omaha","Nebraska","68114",{"type":790,"coordinates":1582},[1583,1584],-95.94043,41.25626,{"lat":1584,"lon":1583},[1587,1589],{"name":797,"role":798,"phone":1588,"phoneExt":82,"email":82},"402-955-3949",{"name":1590,"role":779,"phone":82,"phoneExt":82,"email":82},"Jill C. Beck",{"facility":1592,"status":783,"city":1593,"state":1594,"zip":1595,"country":787,"countryCode":788,"cosmosGeoPoint":1596,"geoPoint":1600,"contacts":1601},"Alliance for Childhood Diseases\u002FCure 4 the Kids Foundation","Las Vegas","Nevada","89135",{"type":790,"coordinates":1597},[1598,1599],-115.13722,36.17497,{"lat":1599,"lon":1598},[1602,1605],{"name":797,"role":798,"phone":1603,"phoneExt":82,"email":1604},"702-384-0013","research@sncrf.org",{"name":1606,"role":779,"phone":82,"phoneExt":82,"email":82},"Alan K. Ikeda",{"facility":1608,"status":783,"city":1609,"state":1610,"zip":1611,"country":787,"countryCode":788,"cosmosGeoPoint":1612,"geoPoint":1616,"contacts":1617},"Dartmouth Hitchcock Medical Center\u002FDartmouth Cancer Center","Lebanon","New Hampshire","03756",{"type":790,"coordinates":1613},[1614,1615],-72.25176,43.64229,{"lat":1615,"lon":1614},[1618,1621],{"name":797,"role":798,"phone":1619,"phoneExt":82,"email":1620},"800-639-6918","cancer.research.nurse@dartmouth.edu",{"name":1622,"role":779,"phone":82,"phoneExt":82,"email":82},"Angela Ricci",{"facility":1624,"status":783,"city":1625,"state":1626,"zip":1627,"country":787,"countryCode":788,"cosmosGeoPoint":1628,"geoPoint":1632,"contacts":1633},"Hackensack University Medical Center","Hackensack","New Jersey","07601",{"type":790,"coordinates":1629},[1630,1631],-74.04347,40.88593,{"lat":1631,"lon":1630},[1634,1636],{"name":797,"role":798,"phone":1635,"phoneExt":82,"email":82},"551-996-2897",{"name":1637,"role":779,"phone":82,"phoneExt":82,"email":82},"Jing Chen",{"facility":1639,"status":783,"city":1640,"state":1626,"zip":1641,"country":787,"countryCode":788,"cosmosGeoPoint":1642,"geoPoint":1646,"contacts":1647},"Morristown Medical Center","Morristown","07960",{"type":790,"coordinates":1643},[1644,1645],-74.48154,40.79677,{"lat":1645,"lon":1644},[1648,1650],{"name":797,"role":798,"phone":1649,"phoneExt":82,"email":82},"973-971-5900",{"name":1651,"role":779,"phone":82,"phoneExt":82,"email":82},"Kathryn L. Laurie",{"facility":1653,"status":783,"city":1654,"state":1626,"zip":1655,"country":787,"countryCode":788,"cosmosGeoPoint":1656,"geoPoint":1660,"contacts":1661},"Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital","New Brunswick","08903",{"type":790,"coordinates":1657},[1658,1659],-74.45182,40.48622,{"lat":1659,"lon":1658},[1662,1664],{"name":797,"role":798,"phone":1663,"phoneExt":82,"email":82},"732-235-8675",{"name":1665,"role":779,"phone":82,"phoneExt":82,"email":82},"Marissa Botwinick",{"facility":1667,"status":783,"city":1668,"state":1626,"zip":1669,"country":787,"countryCode":788,"cosmosGeoPoint":1670,"geoPoint":1674,"contacts":1675},"Saint Joseph's Regional Medical Center","Paterson","07503",{"type":790,"coordinates":1671},[1672,1673],-74.17181,40.91677,{"lat":1673,"lon":1672},[1676,1679],{"name":797,"role":798,"phone":1677,"phoneExt":82,"email":1678},"973-754-2207","HallL@sjhmc.org",{"name":1680,"role":779,"phone":82,"phoneExt":82,"email":82},"Alissa Kahn",{"facility":1682,"status":783,"city":1683,"state":1684,"zip":1685,"country":787,"countryCode":788,"cosmosGeoPoint":1686,"geoPoint":1690,"contacts":1691},"Albany Medical Center","Albany","New York","12208",{"type":790,"coordinates":1687},[1688,1689],-73.75623,42.65258,{"lat":1689,"lon":1688},[1692,1694],{"name":797,"role":798,"phone":1693,"phoneExt":82,"email":82},"518-262-5513",{"name":1695,"role":779,"phone":82,"phoneExt":82,"email":82},"Lauren R. Weintraub",{"facility":1697,"status":783,"city":1698,"state":1684,"zip":1699,"country":787,"countryCode":788,"cosmosGeoPoint":1700,"geoPoint":1704,"contacts":1705},"Roswell Park Cancer Institute","Buffalo","14263",{"type":790,"coordinates":1701},[1702,1703],-78.87837,42.88645,{"lat":1703,"lon":1702},[1706,1709],{"name":797,"role":798,"phone":1707,"phoneExt":82,"email":1708},"800-767-9355","askroswell@roswellpark.org",{"name":1710,"role":779,"phone":82,"phoneExt":82,"email":82},"Lisa Niswander",{"facility":1712,"status":783,"city":1713,"state":1684,"zip":1714,"country":787,"countryCode":788,"cosmosGeoPoint":1715,"geoPoint":1719,"contacts":1720},"The Steven and Alexandra Cohen Children's Medical Center of New York","New Hyde Park","11040",{"type":790,"coordinates":1716},[1717,1718],-73.68791,40.7351,{"lat":1718,"lon":1717},[1721,1723],{"name":797,"role":798,"phone":1722,"phoneExt":82,"email":82},"718-470-3460",{"name":1724,"role":779,"phone":82,"phoneExt":82,"email":82},"Julie I. Krystal",{"facility":1726,"status":783,"city":1684,"state":1684,"zip":1727,"country":787,"countryCode":788,"cosmosGeoPoint":1728,"geoPoint":1732,"contacts":1733},"Laura and Isaac Perlmutter Cancer Center at NYU Langone","10016",{"type":790,"coordinates":1729},[1730,1731],-74.00597,40.71427,{"lat":1731,"lon":1730},[1734,1736],{"name":797,"role":798,"phone":82,"phoneExt":82,"email":1735},"CancerTrials@nyulangone.org",{"name":1737,"role":779,"phone":82,"phoneExt":82,"email":82},"Elizabeth A. Raetz",{"facility":1739,"status":783,"city":1684,"state":1684,"zip":1740,"country":787,"countryCode":788,"cosmosGeoPoint":1741,"geoPoint":1743,"contacts":1744},"Memorial Sloan Kettering Cancer Center","10065",{"type":790,"coordinates":1742},[1730,1731],{"lat":1731,"lon":1730},[1745,1747],{"name":797,"role":798,"phone":1746,"phoneExt":82,"email":82},"212-639-7592",{"name":1748,"role":779,"phone":82,"phoneExt":82,"email":82},"Kavitha Ramaswamy",{"facility":1750,"status":783,"city":1684,"state":1684,"zip":1740,"country":787,"countryCode":788,"cosmosGeoPoint":1751,"geoPoint":1753,"contacts":1754},"NYP\u002FWeill Cornell Medical Center",{"type":790,"coordinates":1752},[1730,1731],{"lat":1731,"lon":1730},[1755,1757],{"name":797,"role":798,"phone":1756,"phoneExt":82,"email":82},"212-746-1848",{"name":1758,"role":779,"phone":82,"phoneExt":82,"email":82},"Jaclyn Rosenzweig",{"facility":1760,"status":783,"city":1761,"state":1684,"zip":1762,"country":787,"countryCode":788,"cosmosGeoPoint":1763,"geoPoint":1767,"contacts":1768},"University of Rochester","Rochester","14642",{"type":790,"coordinates":1764},[1765,1766],-77.61556,43.15478,{"lat":1766,"lon":1765},[1769,1771],{"name":797,"role":798,"phone":1770,"phoneExt":82,"email":82},"585-275-5830",{"name":1772,"role":779,"phone":82,"phoneExt":82,"email":82},"Carol Fries Simpson",{"facility":1774,"status":783,"city":1775,"state":1684,"zip":1776,"country":787,"countryCode":788,"cosmosGeoPoint":1777,"geoPoint":1781,"contacts":1782},"State University of New York Upstate Medical University","Syracuse","13210",{"type":790,"coordinates":1778},[1779,1780],-76.14742,43.04812,{"lat":1780,"lon":1779},[1783,1785],{"name":797,"role":798,"phone":1784,"phoneExt":82,"email":82},"315-464-5476",{"name":1786,"role":779,"phone":82,"phoneExt":82,"email":82},"Melanie A. Comito",{"facility":1788,"status":783,"city":1789,"state":1684,"zip":1790,"country":787,"countryCode":788,"cosmosGeoPoint":1791,"geoPoint":1795,"contacts":1796},"Montefiore Medical Center - Moses Campus","The Bronx","10467",{"type":790,"coordinates":1792},[1793,1794],-73.86641,40.84985,{"lat":1794,"lon":1793},[1797,1800],{"name":797,"role":798,"phone":1798,"phoneExt":82,"email":1799},"718-379-6866","eskwak@montefiore.org",{"name":1801,"role":779,"phone":82,"phoneExt":82,"email":82},"Alice Lee",{"facility":1803,"status":783,"city":1804,"state":1684,"zip":1805,"country":787,"countryCode":788,"cosmosGeoPoint":1806,"geoPoint":1810,"contacts":1811},"New York Medical College","Valhalla","10595",{"type":790,"coordinates":1807},[1808,1809],-73.77513,41.07482,{"lat":1809,"lon":1808},[1812,1814],{"name":797,"role":798,"phone":1813,"phoneExt":82,"email":82},"914-594-3794",{"name":1815,"role":779,"phone":82,"phoneExt":82,"email":82},"Andrew J. Bellantoni",{"facility":1817,"status":783,"city":1818,"state":1819,"zip":1820,"country":787,"countryCode":788,"cosmosGeoPoint":1821,"geoPoint":1825,"contacts":1826},"UNC Lineberger Comprehensive Cancer Center","Chapel Hill","North Carolina","27599",{"type":790,"coordinates":1822},[1823,1824],-79.05584,35.9132,{"lat":1824,"lon":1823},[1827,1830],{"name":797,"role":798,"phone":1828,"phoneExt":82,"email":1829},"877-668-0683","cancerclinicaltrials@med.unc.edu",{"name":1831,"role":779,"phone":82,"phoneExt":82,"email":82},"Thomas B. Alexander",{"facility":1833,"status":783,"city":1834,"state":1819,"zip":1835,"country":787,"countryCode":788,"cosmosGeoPoint":1836,"geoPoint":1840,"contacts":1841},"Carolinas Medical Center\u002FLevine Cancer Institute","Charlotte","28203",{"type":790,"coordinates":1837},[1838,1839],-80.84313,35.22709,{"lat":1839,"lon":1838},[1842,1844],{"name":797,"role":798,"phone":1843,"phoneExt":82,"email":82},"800-804-9376",{"name":1845,"role":779,"phone":82,"phoneExt":82,"email":82},"Joel A. Kaplan",{"facility":1847,"status":783,"city":1848,"state":1819,"zip":1849,"country":787,"countryCode":788,"cosmosGeoPoint":1850,"geoPoint":1854,"contacts":1855},"Duke University Medical Center","Durham","27710",{"type":790,"coordinates":1851},[1852,1853],-78.89862,35.99403,{"lat":1853,"lon":1852},[1856,1858],{"name":797,"role":798,"phone":1857,"phoneExt":82,"email":82},"888-275-3853",{"name":1859,"role":779,"phone":82,"phoneExt":82,"email":82},"Jessica M. Sun",{"facility":1861,"status":783,"city":1862,"state":1819,"zip":1863,"country":787,"countryCode":788,"cosmosGeoPoint":1864,"geoPoint":1868,"contacts":1869},"East Carolina University","Greenville","27834",{"type":790,"coordinates":1865},[1866,1867],-77.36635,35.61266,{"lat":1867,"lon":1866},[1870,1873],{"name":797,"role":798,"phone":1871,"phoneExt":82,"email":1872},"252-744-1015","eubankss@ecu.edu",{"name":1874,"role":779,"phone":82,"phoneExt":82,"email":82},"Andrea R. Whitfield",{"facility":1876,"status":783,"city":1877,"state":1819,"zip":1878,"country":787,"countryCode":788,"cosmosGeoPoint":1879,"geoPoint":1883,"contacts":1884},"Wake Forest University Health Sciences","Winston-Salem","27157",{"type":790,"coordinates":1880},[1881,1882],-80.24422,36.09986,{"lat":1882,"lon":1881},[1885,1887],{"name":797,"role":798,"phone":1886,"phoneExt":82,"email":82},"336-713-6771",{"name":1888,"role":779,"phone":82,"phoneExt":82,"email":82},"Sarah Supples",{"facility":1890,"status":783,"city":1891,"state":1892,"zip":1893,"country":787,"countryCode":788,"cosmosGeoPoint":1894,"geoPoint":1898,"contacts":1899},"Sanford Broadway Medical Center","Fargo","North Dakota","58122",{"type":790,"coordinates":1895},[1896,1897],-96.7898,46.87719,{"lat":1897,"lon":1896},[1900,1903],{"name":797,"role":798,"phone":1901,"phoneExt":82,"email":1902},"701-323-5760","OncologyClinicalTrialsFargo@sanfordhealth.org",{"name":1904,"role":779,"phone":82,"phoneExt":82,"email":82},"Samuel J. Milanovich",{"facility":1906,"status":783,"city":1907,"state":1908,"zip":1909,"country":787,"countryCode":788,"cosmosGeoPoint":1910,"geoPoint":1914,"contacts":1915},"Children's Hospital Medical Center of Akron","Akron","Ohio","44308",{"type":790,"coordinates":1911},[1912,1913],-81.51901,41.08144,{"lat":1913,"lon":1912},[1916,1918],{"name":797,"role":798,"phone":1917,"phoneExt":82,"email":82},"330-543-3193",{"name":1919,"role":779,"phone":82,"phoneExt":82,"email":82},"Erin Wright",{"facility":1921,"status":783,"city":1922,"state":1908,"zip":1923,"country":787,"countryCode":788,"cosmosGeoPoint":1924,"geoPoint":1928,"contacts":1929},"Cincinnati Children's Hospital Medical Center","Cincinnati","45229",{"type":790,"coordinates":1925},[1926,1927],-84.51439,39.12711,{"lat":1927,"lon":1926},[1930,1933],{"name":797,"role":798,"phone":1931,"phoneExt":82,"email":1932},"513-636-2799","cancer@cchmc.org",{"name":1934,"role":779,"phone":82,"phoneExt":82,"email":82},"Erin H. Breese",{"facility":1936,"status":783,"city":1937,"state":1908,"zip":1938,"country":787,"countryCode":788,"cosmosGeoPoint":1939,"geoPoint":1943,"contacts":1944},"Rainbow Babies and Childrens Hospital","Cleveland","44106",{"type":790,"coordinates":1940},[1941,1942],-81.69541,41.4995,{"lat":1942,"lon":1941},[1945,1947],{"name":797,"role":798,"phone":1946,"phoneExt":82,"email":82},"216-844-5437",{"name":1948,"role":779,"phone":82,"phoneExt":82,"email":82},"Duncan S. Stearns",{"facility":1950,"status":783,"city":1951,"state":1908,"zip":1952,"country":787,"countryCode":788,"cosmosGeoPoint":1953,"geoPoint":1957,"contacts":1958},"Dayton Children's Hospital","Dayton","45404",{"type":790,"coordinates":1954},[1955,1956],-84.19161,39.75895,{"lat":1956,"lon":1955},[1959,1961],{"name":797,"role":798,"phone":1960,"phoneExt":82,"email":82},"800-228-4055",{"name":1962,"role":779,"phone":82,"phoneExt":82,"email":82},"Jordan M. Wright",{"facility":1964,"status":783,"city":1965,"state":1908,"zip":1966,"country":787,"countryCode":788,"cosmosGeoPoint":1967,"geoPoint":1971,"contacts":1972},"ProMedica Toledo Hospital\u002FRussell J Ebeid Children's Hospital","Toledo","43606",{"type":790,"coordinates":1968},[1969,1970],-83.55521,41.66394,{"lat":1970,"lon":1969},[1973,1976],{"name":797,"role":798,"phone":1974,"phoneExt":82,"email":1975},"419-824-1842","PCIOncResearch@promedica.org",{"name":1977,"role":779,"phone":82,"phoneExt":82,"email":82},"Jamie L. Dargart",{"facility":1979,"status":783,"city":1980,"state":1981,"zip":1982,"country":787,"countryCode":788,"cosmosGeoPoint":1983,"geoPoint":1987,"contacts":1988},"University of Oklahoma Health Sciences Center","Oklahoma City","Oklahoma","73104",{"type":790,"coordinates":1984},[1985,1986],-97.51643,35.46756,{"lat":1986,"lon":1985},[1989,1992],{"name":797,"role":798,"phone":1990,"phoneExt":82,"email":1991},"405-271-8777","ou-clinical-trials@ouhsc.edu",{"name":1993,"role":779,"phone":82,"phoneExt":82,"email":82},"Rene Y. McNall-Knapp",{"facility":1995,"status":783,"city":1996,"state":1997,"zip":1998,"country":787,"countryCode":788,"cosmosGeoPoint":1999,"geoPoint":2003,"contacts":2004},"Lehigh Valley Hospital-Cedar Crest","Allentown","Pennsylvania","18103",{"type":790,"coordinates":2000},[2001,2002],-75.49018,40.60843,{"lat":2002,"lon":2001},[2005,2008],{"name":797,"role":798,"phone":2006,"phoneExt":82,"email":2007},"610-402-9543","Morgan_M.Horton@lvhn.org",{"name":2009,"role":779,"phone":82,"phoneExt":82,"email":82},"Jacob A. Troutman",{"facility":2011,"status":783,"city":2012,"state":1997,"zip":2013,"country":787,"countryCode":788,"cosmosGeoPoint":2014,"geoPoint":2018,"contacts":2019},"Geisinger Medical Center","Danville","17822",{"type":790,"coordinates":2015},[2016,2017],-76.61273,40.96342,{"lat":2017,"lon":2016},[2020,2023],{"name":797,"role":798,"phone":2021,"phoneExt":82,"email":2022},"570-271-5251","cancerresearch@geisinger.edu",{"name":2024,"role":779,"phone":82,"phoneExt":82,"email":82},"Jagadeesh Ramdas",{"facility":2026,"status":783,"city":2027,"state":1997,"zip":2028,"country":787,"countryCode":788,"cosmosGeoPoint":2029,"geoPoint":2033,"contacts":2034},"Penn State Children's Hospital","Hershey","17033",{"type":790,"coordinates":2030},[2031,2032],-76.65025,40.28592,{"lat":2032,"lon":2031},[2035,2037],{"name":797,"role":798,"phone":2036,"phoneExt":82,"email":82},"717-531-6012",{"name":2038,"role":779,"phone":82,"phoneExt":82,"email":82},"Lisa M. McGregor",{"facility":2040,"status":783,"city":2041,"state":1997,"zip":2042,"country":787,"countryCode":788,"cosmosGeoPoint":2043,"geoPoint":2047,"contacts":2048},"Children's Hospital of Philadelphia","Philadelphia","19104",{"type":790,"coordinates":2044},[2045,2046],-75.16362,39.95238,{"lat":2046,"lon":2045},[2049,2052],{"name":797,"role":798,"phone":2050,"phoneExt":82,"email":2051},"267-425-5544","CancerTrials@email.chop.edu",{"name":2053,"role":779,"phone":82,"phoneExt":82,"email":82},"Kathrin M. Bernt",{"facility":2055,"status":783,"city":2056,"state":1997,"zip":2057,"country":787,"countryCode":788,"cosmosGeoPoint":2058,"geoPoint":2062,"contacts":2063},"Children's Hospital of Pittsburgh of UPMC","Pittsburgh","15224",{"type":790,"coordinates":2059},[2060,2061],-79.99589,40.44062,{"lat":2061,"lon":2060},[2064,2067],{"name":797,"role":798,"phone":2065,"phoneExt":82,"email":2066},"412-692-8570","jean.tersak@chp.edu",{"name":2068,"role":779,"phone":82,"phoneExt":82,"email":82},"Jenny Ruiz",{"facility":2070,"status":783,"city":2071,"state":2072,"zip":2073,"country":787,"countryCode":788,"cosmosGeoPoint":2074,"geoPoint":2078,"contacts":2079},"Rhode Island Hospital","Providence","Rhode Island","02903",{"type":790,"coordinates":2075},[2076,2077],-71.41283,41.82399,{"lat":2077,"lon":2076},[2080,2082],{"name":797,"role":798,"phone":2081,"phoneExt":82,"email":82},"401-444-1488",{"name":2083,"role":779,"phone":82,"phoneExt":82,"email":82},"Bradley DeNardo",{"facility":2085,"status":783,"city":2086,"state":2087,"zip":2088,"country":787,"countryCode":788,"cosmosGeoPoint":2089,"geoPoint":2093,"contacts":2094},"Prisma Health Richland Hospital","Columbia","South Carolina","29203",{"type":790,"coordinates":2090},[2091,2092],-81.03481,34.00071,{"lat":2092,"lon":2091},[2095,2098],{"name":797,"role":798,"phone":2096,"phoneExt":82,"email":2097},"864-522-4317","Kim.Williams3@prismahealth.org",{"name":2099,"role":779,"phone":82,"phoneExt":82,"email":82},"Stuart L. Cramer",{"facility":2101,"status":783,"city":1862,"state":2087,"zip":2102,"country":787,"countryCode":788,"cosmosGeoPoint":2103,"geoPoint":2107,"contacts":2108},"BI-LO Charities Children's Cancer Center","29605",{"type":790,"coordinates":2104},[2105,2106],-82.39401,34.85262,{"lat":2106,"lon":2105},[2109,2110],{"name":797,"role":798,"phone":2096,"phoneExt":82,"email":2097},{"name":2111,"role":779,"phone":82,"phoneExt":82,"email":82},"Aniket Saha",{"facility":2113,"status":783,"city":2114,"state":2115,"zip":2116,"country":787,"countryCode":788,"cosmosGeoPoint":2117,"geoPoint":2121,"contacts":2122},"Sanford USD Medical Center - Sioux Falls","Sioux Falls","South Dakota","57117-5134",{"type":790,"coordinates":2118},[2119,2120],-96.72796,43.54369,{"lat":2120,"lon":2119},[2123,2126],{"name":797,"role":798,"phone":2124,"phoneExt":82,"email":2125},"605-312-3320","OncologyClinicalTrialsSF@SanfordHealth.org",{"name":2127,"role":779,"phone":82,"phoneExt":82,"email":82},"Jordan Fritch-Hanson",{"facility":2129,"status":783,"city":2130,"state":2131,"zip":2132,"country":787,"countryCode":788,"cosmosGeoPoint":2133,"geoPoint":2137,"contacts":2138},"East Tennessee Childrens Hospital","Knoxville","Tennessee","37916",{"type":790,"coordinates":2134},[2135,2136],-83.92074,35.96064,{"lat":2136,"lon":2135},[2139,2141],{"name":797,"role":798,"phone":2140,"phoneExt":82,"email":82},"865-541-8266",{"name":2142,"role":779,"phone":82,"phoneExt":82,"email":82},"Susan E. Spiller",{"facility":2144,"status":783,"city":2145,"state":2131,"zip":2146,"country":787,"countryCode":788,"cosmosGeoPoint":2147,"geoPoint":2151,"contacts":2152},"Saint Jude Children's Research Hospital","Memphis","38105",{"type":790,"coordinates":2148},[2149,2150],-90.04898,35.14953,{"lat":2150,"lon":2149},[2153,2156],{"name":797,"role":798,"phone":2154,"phoneExt":82,"email":2155},"888-226-4343","referralinfo@stjude.org",{"name":2157,"role":779,"phone":82,"phoneExt":82,"email":82},"Matthew Rees",{"facility":2159,"status":783,"city":2160,"state":2131,"zip":2161,"country":787,"countryCode":788,"cosmosGeoPoint":2162,"geoPoint":2166,"contacts":2167},"The Children's Hospital at TriStar Centennial","Nashville","37203",{"type":790,"coordinates":2163},[2164,2165],-86.78444,36.16589,{"lat":2165,"lon":2164},[2168,2170],{"name":797,"role":798,"phone":2169,"phoneExt":82,"email":82},"615-342-1919",{"name":2171,"role":779,"phone":82,"phoneExt":82,"email":82},"Clinton M. Carroll",{"facility":2173,"status":783,"city":2160,"state":2131,"zip":2174,"country":787,"countryCode":788,"cosmosGeoPoint":2175,"geoPoint":2177,"contacts":2178},"Vanderbilt University\u002FIngram Cancer Center","37232",{"type":790,"coordinates":2176},[2164,2165],{"lat":2165,"lon":2164},[2179,2181],{"name":797,"role":798,"phone":2180,"phoneExt":82,"email":82},"800-811-8480",{"name":2182,"role":779,"phone":82,"phoneExt":82,"email":82},"Brianna N. Smith",{"facility":2184,"status":783,"city":2185,"state":2186,"zip":2187,"country":787,"countryCode":788,"cosmosGeoPoint":2188,"geoPoint":2192,"contacts":2193},"Dell Children's Medical Center of Central Texas","Austin","Texas","78723",{"type":790,"coordinates":2189},[2190,2191],-97.74306,30.26715,{"lat":2191,"lon":2190},[2194,2197],{"name":797,"role":798,"phone":2195,"phoneExt":82,"email":2196},"512-628-1902","TXAUS-DL-SFCHemonc.research@ascension.org",{"name":2198,"role":779,"phone":82,"phoneExt":82,"email":82},"Shannon M. Cohn",{"facility":2200,"status":783,"city":2201,"state":2186,"zip":2202,"country":787,"countryCode":788,"cosmosGeoPoint":2203,"geoPoint":2207,"contacts":2208},"Driscoll Children's Hospital","Corpus Christi","78411",{"type":790,"coordinates":2204},[2205,2206],-97.39638,27.80058,{"lat":2206,"lon":2205},[2209,2212],{"name":797,"role":798,"phone":2210,"phoneExt":82,"email":2211},"361-694-5311","Crystal.DeLosSantos@dchstx.org",{"name":2213,"role":779,"phone":82,"phoneExt":82,"email":82},"Nkechi I. Mba",{"facility":2215,"status":783,"city":2216,"state":2186,"zip":2217,"country":787,"countryCode":788,"cosmosGeoPoint":2218,"geoPoint":2222,"contacts":2223},"Medical City Dallas Hospital","Dallas","75230",{"type":790,"coordinates":2219},[2220,2221],-96.80667,32.78306,{"lat":2221,"lon":2220},[2224,2226],{"name":797,"role":798,"phone":2225,"phoneExt":82,"email":82},"972-566-5588",{"name":2227,"role":779,"phone":82,"phoneExt":82,"email":82},"Maurizio L. Ghisoli",{"facility":2229,"status":783,"city":2216,"state":2186,"zip":2230,"country":787,"countryCode":788,"cosmosGeoPoint":2231,"geoPoint":2233,"contacts":2234},"UT Southwestern\u002FSimmons Cancer Center-Dallas","75390",{"type":790,"coordinates":2232},[2220,2221],{"lat":2221,"lon":2220},[2235,2238],{"name":797,"role":798,"phone":2236,"phoneExt":82,"email":2237},"214-648-7097","canceranswerline@UTSouthwestern.edu",{"name":2239,"role":779,"phone":82,"phoneExt":82,"email":82},"Caroline Smith",{"facility":2241,"status":783,"city":2242,"state":2186,"zip":2243,"country":787,"countryCode":788,"cosmosGeoPoint":2244,"geoPoint":2248,"contacts":2249},"El Paso Children's Hospital","El Paso","79905",{"type":790,"coordinates":2245},[2246,2247],-106.48693,31.75872,{"lat":2247,"lon":2246},[2250,2253],{"name":797,"role":798,"phone":2251,"phoneExt":82,"email":2252},"915-298-5444","ranjan.bista@ttuhsc.edu",{"name":2254,"role":779,"phone":82,"phoneExt":82,"email":82},"Benjamin Carcamo",{"facility":2256,"status":783,"city":2257,"state":2186,"zip":2258,"country":787,"countryCode":788,"cosmosGeoPoint":2259,"geoPoint":2263,"contacts":2264},"Cook Children's Medical Center","Fort Worth","76104",{"type":790,"coordinates":2260},[2261,2262],-97.32085,32.72541,{"lat":2262,"lon":2261},[2265,2268],{"name":797,"role":798,"phone":2266,"phoneExt":82,"email":2267},"682-885-2103","CookChildrensResearch@cookchildrens.org",{"name":2269,"role":779,"phone":82,"phoneExt":82,"email":82},"Holly Pacenta",{"facility":2271,"status":783,"city":2272,"state":2186,"zip":2273,"country":787,"countryCode":788,"cosmosGeoPoint":2274,"geoPoint":2278,"contacts":2279},"Baylor College of Medicine\u002FDan L Duncan Comprehensive Cancer Center","Houston","77030",{"type":790,"coordinates":2275},[2276,2277],-95.36327,29.76328,{"lat":2277,"lon":2276},[2280,2283],{"name":797,"role":798,"phone":2281,"phoneExt":82,"email":2282},"713-798-1354","burton@bcm.edu",{"name":2284,"role":779,"phone":82,"phoneExt":82,"email":82},"Joanna S. Yi",{"facility":2286,"status":783,"city":2287,"state":2186,"zip":2288,"country":787,"countryCode":788,"cosmosGeoPoint":2289,"geoPoint":2293,"contacts":2294},"Children's Hospital of San Antonio","San Antonio","78207",{"type":790,"coordinates":2290},[2291,2292],-98.49363,29.42412,{"lat":2292,"lon":2291},[2295,2298],{"name":797,"role":798,"phone":2296,"phoneExt":82,"email":2297},"210-704-2894","bridget.medina@christushealth.org",{"name":2299,"role":779,"phone":82,"phoneExt":82,"email":82},"Julie Voeller",{"facility":2301,"status":783,"city":2287,"state":2186,"zip":2302,"country":787,"countryCode":788,"cosmosGeoPoint":2303,"geoPoint":2305,"contacts":2306},"Methodist Children's Hospital of South Texas","78229",{"type":790,"coordinates":2304},[2291,2292],{"lat":2292,"lon":2291},[2307,2310],{"name":797,"role":798,"phone":2308,"phoneExt":82,"email":2309},"210-575-6240","Vinod.GidvaniDiaz@hcahealthcare.com",{"name":2311,"role":779,"phone":82,"phoneExt":82,"email":82},"Jose M. Esquilin",{"facility":2313,"status":783,"city":2314,"state":2315,"zip":2316,"country":787,"countryCode":788,"cosmosGeoPoint":2317,"geoPoint":2321,"contacts":2322},"University of Virginia Cancer Center","Charlottesville","Virginia","22908",{"type":790,"coordinates":2318},[2319,2320],-78.47668,38.02931,{"lat":2320,"lon":2319},[2323,2326],{"name":797,"role":798,"phone":2324,"phoneExt":82,"email":2325},"434-243-6303","uvacancertrials@hscmail.mcc.virginia.edu",{"name":2327,"role":779,"phone":82,"phoneExt":82,"email":82},"Brian C. Belyea",{"facility":2329,"status":783,"city":2330,"state":2315,"zip":2331,"country":787,"countryCode":788,"cosmosGeoPoint":2332,"geoPoint":2336,"contacts":2337},"Children's Hospital of The King's Daughters","Norfolk","23507",{"type":790,"coordinates":2333},[2334,2335],-76.28522,36.84681,{"lat":2335,"lon":2334},[2338,2341],{"name":797,"role":798,"phone":2339,"phoneExt":82,"email":2340},"757-668-7243","CCBDCresearch@chkd.org",{"name":2342,"role":779,"phone":82,"phoneExt":82,"email":82},"Melissa S. Mark",{"facility":2344,"status":783,"city":2345,"state":2315,"zip":2346,"country":787,"countryCode":788,"cosmosGeoPoint":2347,"geoPoint":2351,"contacts":2352},"VCU Massey Comprehensive Cancer Center","Richmond","23298",{"type":790,"coordinates":2348},[2349,2350],-77.46026,37.55376,{"lat":2350,"lon":2349},[2353,2356],{"name":797,"role":798,"phone":2354,"phoneExt":82,"email":2355},"804-628-6430","CTOclinops@vcu.edu",{"name":2357,"role":779,"phone":82,"phoneExt":82,"email":82},"Jordyn R. Griffin",{"facility":2359,"status":783,"city":2360,"state":2315,"zip":2361,"country":787,"countryCode":788,"cosmosGeoPoint":2362,"geoPoint":2366,"contacts":2367},"Carilion Children's","Roanoke","24014",{"type":790,"coordinates":2363},[2364,2365],-79.94143,37.27097,{"lat":2365,"lon":2364},[2368,2371],{"name":797,"role":798,"phone":2369,"phoneExt":82,"email":2370},"540-266-6238","wpmccarty@carilionclinic.org",{"name":2372,"role":779,"phone":82,"phoneExt":82,"email":82},"Erwood G. Edwards",{"facility":2374,"status":783,"city":2375,"state":2376,"zip":2377,"country":787,"countryCode":788,"cosmosGeoPoint":2378,"geoPoint":2382,"contacts":2383},"Seattle Children's Hospital","Seattle","Washington","98105",{"type":790,"coordinates":2379},[2380,2381],-122.33207,47.60621,{"lat":2381,"lon":2380},[2384,2386],{"name":797,"role":798,"phone":2385,"phoneExt":82,"email":82},"866-987-2000",{"name":2387,"role":779,"phone":82,"phoneExt":82,"email":82},"Sarah E. Leary",{"facility":2389,"status":783,"city":2390,"state":2376,"zip":2391,"country":787,"countryCode":788,"cosmosGeoPoint":2392,"geoPoint":2396,"contacts":2397},"Providence Sacred Heart Medical Center and Children's Hospital","Spokane","99204",{"type":790,"coordinates":2393},[2394,2395],-117.42908,47.65966,{"lat":2395,"lon":2394},[2398,2401],{"name":797,"role":798,"phone":2399,"phoneExt":82,"email":2400},"800-228-6618","HopeBeginsHere@providence.org",{"name":2402,"role":779,"phone":82,"phoneExt":82,"email":82},"Judy L. Felgenhauer",{"facility":2404,"status":783,"city":2405,"state":2406,"zip":2407,"country":787,"countryCode":788,"cosmosGeoPoint":2408,"geoPoint":2412,"contacts":2413},"Saint Vincent Hospital Cancer Center Green Bay","Green Bay","Wisconsin","54301",{"type":790,"coordinates":2409},[2410,2411],-88.01983,44.51916,{"lat":2411,"lon":2410},[2414,2417],{"name":797,"role":798,"phone":2415,"phoneExt":82,"email":2416},"920-433-8889","WI_research_admin@hshs.org",{"name":2418,"role":779,"phone":82,"phoneExt":82,"email":82},"Catherine A. Long",{"facility":2420,"status":783,"city":2421,"state":2406,"zip":2422,"country":787,"countryCode":788,"cosmosGeoPoint":2423,"geoPoint":2427,"contacts":2428},"Children's Hospital of Wisconsin","Milwaukee","53226",{"type":790,"coordinates":2424},[2425,2426],-87.90647,43.0389,{"lat":2426,"lon":2425},[2429,2432],{"name":797,"role":798,"phone":2430,"phoneExt":82,"email":2431},"414-955-4727","MACCCTO@mcw.edu",{"name":2433,"role":779,"phone":82,"phoneExt":82,"email":82},"Zachary Graff",{"facility":2435,"status":783,"city":2436,"state":82,"zip":2437,"country":2438,"countryCode":2439,"cosmosGeoPoint":2440,"geoPoint":2444,"contacts":2445},"University Pediatric Hospital","San Juan","00926","Puerto Rico","PR",{"type":790,"coordinates":2441},[2442,2443],-66.10572,18.46633,{"lat":2443,"lon":2442},[2446,2448],{"name":797,"role":798,"phone":2447,"phoneExt":82,"email":82},"787-474-0333",{"name":2449,"role":779,"phone":82,"phoneExt":82,"email":82},"Maria E. Echevarria",{"type":2451,"investigatorFullName":82,"investigatorTitle":82,"investigatorAffiliation":82,"oldNameTitle":82,"oldOrganization":82},"SPONSOR","100540501","phase-2-testing-the-addition-of-the-anti-cancer-drug-venetoclax-andor-the-anti-cancer-immunotherapy-blinatumomab-to-the-usual-chemotherapy-treatment-for-infants-with-newly-diagnosed-kmt2a-rearranged-or-kmt2a-non-rearranged-leukemia-100540501",false,"NCT06317662","Testing the Addition of the Anti-cancer Drug Venetoclax and\u002For the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax","Inclusion Criteria:\n\n* All patients must be enrolled on APEC14B1 and consented to eligibility screening (part A) prior to treatment and enrollment on AALL2321\n* Infants (aged 365 days or less) on the date of diagnosis are eligible; infants must be \\> 36 weeks gestational age (cumulative prenatal and postnatal age must be \\> 36 weeks) at the time of enrollment\n* Patients must have newly diagnosed B-acute lymphoblastic leukemia (B-ALL, 2017 World Health Organization \\[WHO\\] classification), also termed B-precursor ALL, or acute leukemia of ambiguous lineage (ALAL), which includes mixed phenotype acute leukemia. For patients with ALAL, the immunophenotype of the leukemia must comprise at least 50% B lineage\n\n  * Diagnostic immunophenotype: Leukemia cells must express CD19\n\nExclusion Criteria:\n\n* Patients with Down Syndrome\n* Patients with secondary B-ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy\n* Patients must not have received any cytotoxic chemotherapy for either the current diagnosis of infant ALL or for any cancer diagnosis prior to the initiation of protocol therapy, with the exception of:\n\n  * Steroid pretreatment:\n\n    * PredniSONE, prednisoLONE, or methylPREDNISolone for ≤ 72 hours (3 days) in the 7 days prior to enrollment. The dose of predniSONE, prednisoLONE or methylPREDNISolone does not affect eligibility\n    * Inhaled and topical steroids are not considered pretreatment\n    * Note: Pretreatment with dexamethasone in the 28 days prior to initiation of protocol therapy is not allowed with the exception of a single dose of dexamethasone used during or within 6 hours prior to or after sedation to prevent or treat airway edema. However, prior exposure to ANY steroids that occurred \\> 28 days before enrollment does not affect eligibility\n  * Intrathecal cytarabine or methotrexate:\n\n    * An intrathecal dose of cytarabine or methotrexate in the 7 days prior to enrollment does not affect eligibility\n    * Note: The preference is to defer the diagnostic lumbar puncture with intrathecal chemotherapy to day 1 of induction to allow for cytoreduction of circulating blasts and decrease the potential for central nervous system (CNS) contamination due to a traumatic tap. If done prior to day 1 of induction, these results will be used to determine CNS status\n  * Hydroxyurea:\n\n    * Pretreatment with ≤ 72 hours (3 days) of hydroxyurea in the 7 days prior to enrollment does not affect eligibility\n* All patients and\u002For their parents or legal guardians must sign a written informed consent\n* All institutional, Food and Drug Administration (FDA) and National Cancer Institute (NCI) requirements for human studies must be met","ALL","365 Days",{"count":2462,"type":2463},153,"ESTIMATED","INTERVENTIONAL",[2466],"PHASE2","This phase II trial tests the addition of venetoclax and\u002For blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \\[R\\]) or without a KMT2A gene rearrangement (KMT2A-germline \\[G\\]). Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax and\u002For blinatumomab to standard chemotherapy may be more effective at treating patients with ALL than standard chemotherapy alone, but it may also cause more side effects. This clinical trial evaluates the safety and effectiveness of adding venetoclax and\u002For blinatumomab to chemotherapy for the treatment of infants with KMT2A-R or KMT2A-G ALL.",[2469,2470],"Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia","2026-09-15",{"date":2473,"type":2474},"2026-09-16","ACTUAL",{"date":2476,"type":2474},"2025-06-05",{"date":2478,"type":2463},"2028-12-31",{"name":5,"class":6},115]